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Primary platelet adhesion to vascular collagen has a fundamental role in haemostasis.
Not only does it anchor platelets to the site of injury, such as a bleeding wound, but it
also initiates complex intracellular reactions resulting in platelet interaction with other
platelets, i.e., formation of a platelet aggregate. Furthermore, in addition to releasing
activating substances, collagen-adherent platelets enhance the generation of thrombin,
the culmination of the coagulation cascade leading to the formation of a fibrin-stabi-
lised plug of aggregated platelets. This step is critically dependent on the transforma-
tion of the platelet membrane into a catalytic surface via the exposure of anionic
aminophospholipids and shedding of microparticles. Platelet-derived microparticles have
previously been shown to associate with enhanced coagulation, and their generation is
reminiscent of cell vesiculation during apoptosis, programmed cell death. However, the
mechanisms of microparticle induction and the functional significance of their genera-
tion are still poorly known, despite their original recognition 30 years ago.
Interaction of platelets with vessel wall collagen is influenced by many rheological
factors, and in platelets, several putative collagen-binding receptors have been pro-
posed. Of these, only the integrin α
2
β
1
 or glycoprotein (GP) Ia/IIa has acquired an
established role in the primary adhesion, and recently, GPVI was recognised as an
important activating receptor, acting subsequent to platelet immobilisation via GPIa/IIa
in the so-called two-site two-step model. Nonetheless, the role of the other putative
receptors and the sequence of events from adhesion to full platelet activation are far
from clear.
In the present series of investigations special emphasis was applied to in vivo -like
experimentation. Both the platelet-collagen interaction and the formation of platelet-
derived microparticles were studied with native type I collagen fibrils under whole
blood flow, mimicking conditions occurring in the vasculature. Furthermore, the de-
tailed molecular mechanisms of platelet procoagulant reaction were studied in situ on
collagen and collagen-related substrates. These studies provide new information on
the participating receptors and on the sequence of events of platelet-collagen interac-
tion, from the initial adhesion step culminating in the final thrombin-forming and
microparticle-generating transformation of platelets.
Myocardial infarction, stroke and peripheral arterial disease are all dire thrombotic
manifestations of an ill-regulated haemostatic response on a ruptured or fissured athero-
sclerotic plaque. While the initial formation and development of the atheromatous ves-
sel wall are being resisted at the cholesterol frontier, studying the actual haemostasis
and its regulatory mechanisms may provide immediate tools to reduce the thrombotic
events which still account for the majority of deaths in the western society.
Introduction
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1. PLATELETS
Platelets are small anucleate cells, which are generated by the fragmentation of
megakaryocytes in the bone marrow and in the vasculature. On average, in human
blood 75-200 x1010 platelets circulate approximately for 10 days before they turn se-
nescent and are removed by phagocytosis of macrophages118.
Blood is isolated from the surrounding thrombogenic tissue by an insulating endothelial
cell layer, which actively opposes thrombus formation. The main function of blood
platelets is to undertake hemostasis. Upon vascular injury, circulating platelets come
into contact with the exposed matrix proteins and start to adhere. This initial adherent
layer of platelets becomes activated and subsequently, more platelets are recruited to
adhere to one another forming an aggregate. The activated platelets can also facilitate
the generation of thrombin, a key enzyme of the coagulation cascade, which finally
stabilises the platelet plug by forming fibrin (Figure 1). The fibrin network ultimately
seals the formed thrombus preventing extra-circulatory blood loss. Finally, clot retrac-
tion pulls the opposite sides of the wound together and mediators secreted by platelets
stimulate entry and growth of endothelial cells, smooth muscle cells and fibroblasts
ensuring proper wound healing.
Figure 1. Model of sequential adhesion and activation events during platelet-
interaction with subendothelial proteins, e.g., collagen. Adapted from
Clemetson 199959.
In pathological states such as atherosclerosis, the diseased vessel wall can lead to the
generation of a thrombus in the absence of true trauma. Such uncontrolled occlusion of
blood vessels is manifested, for example, in myocardial infarction or stroke (reviewed
in111; 112). Increased platelet activation has also been associated with early phases of
atherosclerosis and restenosis234; 273; 301.
Intact endothelium ThrombusSpread platelet
Circulating resting
platelets
Adhesion to exposed
subendothelium
Platelet activation 
and aggregation
Microvesiculation
vWf and collagen
Fibrin network
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1.1. Platelet adhesion and activation
When platelets come into contact with vascular matrix proteins such as collagen, they
change shape and adhere firmly. Platelets richly express adhesion receptors belonging
to the integrin, leucine-rich motif, immunoglobulin and selectin families among others.
Integrins may function both in the primary adhesion, e.g. α
2
β
1
 in platelet adhesion to
collagen, or in the final events where α
IIb
β
3
, the integrin specific for platelets, is re-
sponsible for fibrinogen- or von Willebrand factor (vWf)-mediated aggregation and
thrombus formation. Glycoprotein (GP) Ib, characterised by the presence of leucine-
rich domains, is important in the primary adhesive interaction with collagen-bound or
vascular vWf. The immunoglobulin superfamily members are involved with various
adhesion events ranging from cell-matrix to cell-cell interactions. Finally, P-selectin,
the only member of the selectin family in platelets, is expressed on platelet membrane
only after granule secretion and is required for interactions with leukocytes. These
examples of the protein receptor families portray the importance of adhesion in all
phases of platelet function.
Platelets also need to become activated to exert their full effector capacity. Activation
occurs through platelet adhesion receptors while binding to extracellular matrix pro-
teins such as collagen, or by soluble agonists such as thrombin, adenosine diphosphate
(ADP), and epinephrine. The sources of the soluble agonists are circulating blood,
blood cells and the endothelium. In a full-blown platelet response a multitude of agonists
are involved and platelets become also auto-activating. Platelets carry specific receptors
for their soluble agonists, most of which are the G-protein-coupled, so-called seven
transmembrane- or serpentine receptors (reviewed in32; 39).
The interaction of agonists with their specific receptors initiates signal transduction, a
multiphasic activation sequence of a plethora of intracellular second messengers (re-
viewed in32; 39; 195; 288; 289). Platelets contain many signalling pathways that may inter-
act, either down- or up-regulate each other, and despite their anuclear status platelets
possess signalling routes that in nucleated cells lead to cell proliferation and matura-
tion. Platelet activators have traditionally been divided into strong and weak agonists
based on their capacity to induce granule secretion even when aggregation is inhib-
ited37. However, the “strength” of the agonist depends mostly on their capacity to
induce intracellular signalling. Whereas strong agonists such as collagen and thrombin
activate several pathways and induce significant calcium (Ca2+)-mobilisation, weak
agonists like ADP and epinephrine activate these pathways only partially.
In general, intracellular signalling in platelets involves activation of phospholipase C
(PLC), which leads to subsequent activation of protein kinase C (PKC) and rise in
intracellular calcium via release of diacylglycerol and inositol trisphosphate, respec-
tively. Furthermore cytosolic phospholipase A
2
 (cPLA
2
) becomes activated and re-
leases arachidonic acid (AA), the precursor of several eicosanoids, such as thromboxane
A
2
 (TxA
2
). TxA
2 
is produced by the aspirin-sensitive cyclo-oxygenase pathway and
augments platelet activation via TxA
2
 receptors. The intracellular levels of aggrega-
tion-inhibiting cyclic nucleotides decrease due to the inhibition of adenylate and guanylate
cyclases. Release of dense granules liberates ADP and serotonin, each capable of
activating their own receptors on the platelet membrane. Experiments with various
Review of the literature
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kinase and phosphatase inhibitors have shown that protein phosphorylation is crucial
for the activation of α
IIb
β
3 
integrin, i.e. GPIIb/IIIa, the name most often used for this
receptor in platelet literature321. In addition to liberating ADP and TxA
2
, and thus
further inducing GPIIb/IIIa activation47, strong agonists collagen and thrombin can
directly activate GPIIb/IIIa via PKC321.
1.2. Platelet morphology, secretion and molecular changes of plasma membrane
Resting platelets have a discoid-ellipsoid shape (1.5-2.5 µm in diameter) with large
membrane invaginations forming the open (OCS) or surface-connected canaliculiar
system (SCCS). Upon adhesion or activation, platelets become spherical with the con-
comitant extrusion of filopodia greatly increasing contacts with the environment 37; 329.
These pseudo- or filopodia can contact adhesive surfaces or other platelets. Spreading
out of the plasma membrane, lamellipodia fill out the gaps inbetween the pseudopodia,
resulting in the formation of a “fried-egg”, a fully spread and flattened platelet with a
central eminence. The size of the spread platelet can reach 7-10 µm in diameter. The
schematic phases of shape change are shown in Figure 2.
Morphological transformation of platelets is based on cytoskeletal rearrangements in-
volving over 14 different proteins, and an increase in actin filament content from 30-
40% up to 60-70% of total actin, when filament bundles form the developing filopodia.
Contraction of the filaments leads to reorganisation of OCS/SCCS, which provides
membrane material for the size expansion during spreading. Cytoskeletal rearrange-
ment-dependent centralisation of platelet organelles in the so-called contractile ring is
associated with secretion, although the fusion site of the organelles is unknown. Plate-
lets contain three types of secretory granules, α- and δ-granules (dense granules) and
lysosomes. When platelets become activated, these granules liberate several func-
tional molecules, which affect both the platelet adhesion-activation process and coagu-
lation, but also other cells in blood and vasculature329.
Figure 2. Schematic picture of changes in platelet morphology during adhe-
sion, activation and aggregate formation.
Resting, discoid,
circulating platelet
Spherical,attached platelet
     with pseudopods Fully spread "fried egg"
An aggregate consisting of 
      several platelets
1 µm
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Activation-dependent platelet transformation induces changes in the surface glycopro-
tein and lipid populations61; 284. Whereas the amount of surface GPIb-V-IX complexes
decrease (although this is still a matter of debate198), GPIIb/IIIa increases and new
protein species appear, e.g. P-selectin, upon granule fusion with the plasma mem-
brane. In addition, intracellular signals and cytoskeletal rearrangements generated by
engagement of the surface receptors modulate both the affinity (conformational change)
and avidity (receptor clustering) of GPIIb/IIIa, which are a prerequisite for aggrega-
tion. The final morphological transformation in platelets is the loss of membrane asym-
metry353. The exposure of negatively charged aminophospholipids on the platelet sur-
face and the concomitant microvesiculation are the essential cornerstones of thrombin
generation (see chapters 1.3. and 5).
1.3. Platelets and coagulation
Blood coagulation can be considered as a host-defence system aimed at maintaining
the vascular integrity110. The plug that the adhering and aggregating platelets form in
the initial phases after tissue injury is stabilised by the conversion of soluble fibrinogen
into an insoluble fibrin network or fibrin clot, the end product of the coagulation cas-
cade (see Figure 3). This network not only seals the formed thrombus, but also traps
further platelets and erythrocytes in it increasing the clot volume. After wound healing,
the clot is subsequently removed by fibrinolysis. The importance of platelets in coagu-
lation may be characterised as a powerful self-enhancing and controlling loop localised
in the injury site in which new thrombin is generated through activation of an increasing
number of platelets28.
The sequential binding of activated cofactors to coagulation factor zymogens and their
proteolytic activation through either the intrinsic or extrinsic pathways culminates in
the conversion of enzymatically inactive prothrombin into multifunctional thrombin.
Thrombin plays a major role not only in coagulation and platelet activation but also in
activating other cells, propagating inflammatory responses, controlling the vascular
tone93and in the regulation of fibrinolysis by, e.g., activating thrombin-activatable fibri-
nolysis inhibitor223. The participation of platelets in the formation of thrombin is essen-
tial because of at least three reasons. Firstly, their negatively charged plasma mem-
brane provides, together with Ca2+-ions, a catalytic surface for the assembly of
procoagulant enzyme-cofactor complexes enhancing thrombin formation 1000-fold204.
Incapacity of platelets to provide the procoagulant surface results in a bleeding compli-
cation as manifested in Scott’s syndrome (reviewed in143). In addition, also the platelet
GPIIb/IIIa receptor has been shown to both bind prothrombin and influence its activa-
tion44. Secondly, platelets contain coagulation factors such as fibrinogen, vWf, factor
V, IX, X, XI and XIII, which are liberated on the site of vascular injury upon platelet
adhesion and activation. For example, the importance of platelet-derived coagulation
factor V is reflected in that, although platelets contain only 20% of the total factor V, a
defect in platelet factor V causes bleeding whereas a patient with neutralised plasma
factor V does not bleed208. Thirdly, platelets shed microparticles capable of expanding
the catalytic phospholipid membrane surface26. Although the role of platelets in the
formation of prothrombinase complex is crucial, it is not solely restricted to platelet
surfaces but can also be formed on erythrocytes240, leukocytes312 and endothelial256
and tumorigenic cells88 and plasma lipoproteins219; 259.
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Figure 3. The intrinsic and extrinsic pathways of coagulation cascade illustrat-
ing the central role of platelet-derived phospholipids and Ca2+ in the formation
of tenase (factors VIIIa, IXa and X) and prothrombinase (factors Va, Xa and
prothrombin) complexes.
A cellular energy-requiring system controls that the negatively charged amino-
phospholipids, such as phosphatidylserine (PS) and phosphatidylethanolamine (PE),
are located in the inner leaflet of the plasma membrane in resting cells. The generation
of prothrombin-converting activity is associated with the loss of membrane asymmetry
and the exposure of these aminophospholipids upon platelet activation24. Especially
important is the activation-mediated influx of Ca2+-ions, which stimulates or inhibits
enzymes responsible for lipid homeostasis. According to a current view, physiologic
intracellular Ca2+-concentration preserves membrane asymmetry by three enzymes:
Ca2+-dependent non-specific scramblase that allows non-discriminating lipid move-
ment between leaflets, Ca2+-dependent translocase, which catches run-away PS and
PE from the outer leaflet and returns them inside, and a non-specific floppase regulat-
ing the normal slow outward-movement of lipids353. Upon micromolar rise in the intra-
cellular Ca2+, scramblase becomes activated and translocase is inactivated resulting in
an efflux of aminophospholipids. Another theory advocates vectorial outflow of
aminophospholipids mediated by a specific floppase23, and considers no role for a gen-
eral phospholipid-scrambling event113.
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Tissue factor-initiated coagulation via the extrinsic pathway is considered to be
haemostatically more important than the intrinsic pathway initiated by contact activa-
tion (Figure 3). Tissue factor, an integral membrane protein expressed on variety of
cells313, binds factor VII and activated VII (VIIa) and catalyses the formation of Xa
either directly, or via IXa, which binds together with activated cofactor VIII to form a
Xa-generating tenase (or Xase) complex. Then thrombin- or Xa-activated cofactor Va
and Xa assemble as a prothrombinase complex catalysing the generation of thrombin
from prothrombin. In all of these conversions, the role of the aminophospholipid sur-
face is at least enhancing or indispensable, including the feedback inhibition of thrombin
generation catalysed by protein C pathway, which inactivates factor Va and VIIIa.353
Whether the prothrombinase and tenase complexes bind to solely lipid surface or uni-
dentified specific receptors is unsettled351; 353. However, the functional role of nega-
tively charged lipid surface and Ca2+ is supported by the capacity of a lipase25 and
annexin V to block thrombin generation4; 308. PS appears to be most important in the
catalytic reaction257, but other phospholipid classes are able to modify the binding ca-
pacity of coagulation factors. For example, PE stimulates thrombin formation and low-
ers the molar proportion of PS needed for the catalysis of maximal thrombin genera-
tion294. In addition, certain phospholipids may have a preference for either pro-or anti-
coagulant factor binding227; 307.
2. COLLAGEN
2.1. Collagen types and haemostasis
Collagens form the most abundant protein family in humans (reviewed in35; 247), and
more than 19 different collagen types (type I-XIX) have been recognised so far. Col-
lagens can be divided into classes based on their fibril-forming capacity. The fibrillar
collagens (I, II, III, V and XI) can organise their full-length triple-helical monomers
into large fibres. In the network-forming collagens (IV, VIII and X), the FACIT (fibril-
associated collagens with interrupted triple helices) collagens (IX, XII, XIV, XVI and
XIX), the beaded (VI) or the anchoring fibril (VII) collagens, and all the rest of cur-
rently known collagen types, the collagenous triple-helical structure is discontinuous.
Interestingly, a few of these collagens have a transmembrane domain (XIII and XVII).
Nine of the collagen types, I, III, IV-VI, VIII and XII-XIV, are present in the vessel
wall. In the vessel wall, the fibril-forming species, I, III and V constitute the majority of
collagens, although the network-forming collagen type IV is spatially enriched in the
basement membrane169. Collagen XIII may also become a component of the extracel-
lular matrix after its proteolytic cleavage from cell membrane.The amount of collagen
varies between 20-40% of total protein in aorta and the smaller arteries, respectively12.
Platelet-reactivity to all vascular collagens except XIII and XIV has been evaluated.
Of these collagens types, I, III and IV are the most platelet-reactive, capable of induc-
ing both adhesion and aggregation, also under conditions of blood flow293. Collagens
type I and III are exposed to platelets mainly when the injury extends to the deeper
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layers of vessel wall, the media or adventitia, but in some vessel matrices these colla-
gens are also found in the subendothelium200. The intimal concentration of these colla-
gens markedly increases during atherosclerosis12; 339. Fibrillar collagen V participates
in organising the other fibrillar collagens. Conversely, type V as such is reported to
induce only static platelet adhesion268.
2.2. Structure of fibrillar collagens
All collagens share a common structure (Figure 4 95). At the level of primary structure,
the tropocollagen molecule consists of three peptide strands, i.e., α-chains, of repeat-
ing triple sequence G-X-Y (1000 amino acids, length 300 nm, width 1.5 nm). Due to
the small size of amino acid glycine (G) each strand forms a left-handed helix. The
backbone position of the helix is occupied by G, while X and Y are turned towards the
external milieu, and together the three amino acids form one turn in the helix 248.
Approximately 100 places of X and Y are frequently occupied by imino acids proline
(P) and hydroxyproline (P*), which is a rare amino acid found almost exclusively in
collagens. The presence of P* ensures stability for the helix at body temperature251. A
unique region of 5-6 consecutive G-X-P* in the carboxy-terminal end of the helical
domain is postulated to act as a nucleation sites for correct tropocollagen folding43.
The three helical α-chains supercoil together in a right-handed triple-helix, forming
thus a very stable and durable structure due to multiple hydrogen bonds. Collagen type
I consists of two α
1
-chains and one α
2
-chain, whereas type III collagen is a disulphide-
bonded homotrimer of α
1
(III). In non-fibrillar collagens the triple-helical parts may
flank other domains, one of which is the inserted (I)- or A-domain shared also by e.g.
integrin α-chains and vWf63.
Figure 4. Molecular features of collagen structure from primary amino acid
sequence up to fibre ultrastructure. Adapted from Eyre 198095.
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Native-type collagen fibrils are formed when single tropocollagen monomers arrange
side-to-side and end-to-end in a quarter-staggered array (Figure 4). The formed fibril
is stabilised by covalent cross-links via lysine and hydroxylysine residues (reviewed
in160). During ageing cross-linking of the fibril increases, while the collagen fibre as-
sumes its tensile strength and insolubility. The type and amount of cross-links also
depend on the tissue type (reviewed in9). The short amino- and carboxy-terminal re-
gions of tropocollagen, called the telopeptides, are essential in the cross-linking proc-
ess, since they contain the majority of the lysines. In type I collagen the telopeptides
range between 11 and 26 amino acids in length. These linear segments are susceptible
to proteolytic attack, e.g. by pepsin, while the triple-helical main body of the molecule
is inert and can only be degraded by special collagenase proteases87; 260. The poly-
meric organisation of collagen monomers in fibrils can be seen as a typical striated
(670 ± 30 Å -band) structure in transmission electron microscopy (TEM). In vivo
collagen fibres can be hybrids of different collagen types, and the FACIT-collagens
associate on the surface of the formed collagen fibrils, e.g., type XII on collagen type
I247. One function for these mixtures is to regulate fibrillogenesis. Also, proteoglycans
like decorin may associate with the fibres affecting their fibril formation and binding
properties286. The essential role of correctly formed cross-linked collagen quaternary
structure is manifested in several pathological states, such as osteogenesis imperfecta137;
165; 249. Lately, the native polymerised collagen was shown to control the cell cycle of
smooth muscle cells by inhibiting proliferation, whereas degradation of the collagen
matrix induced cells to multiply179. Hence the collagen matrix is not only an inert scaf-
folding for cells to bind to, but also its structural state of molecular folding regulates the
activities of the interacting cells. Interestingly, platelets among other cells contain ma-
trix-remodelling collagenases99.
3. PLATELET-COLLAGEN INTERACTION
3.1. Collagen receptors in platelets
The first studies of platelet-collagen interaction in the beginning of 1960s146; 350, de-
scribed the platelet-aggregating capacity of saline extracts from tissue samples. Ag-
gregation by the method of Born was the first technique available for analysing the
effects of platelet–collagen interaction34. However, this method is unable to distinguish
between the processes of adhesion and activation leading to the involvement of GPIIb/
IIIa. Experimental analysis of receptors using affinity columns with immobilised colla-
gen or radiolabeled platelets in static adhesion assays has been hampered by the com-
plex multistep and -receptor process. Also, the capacity of several proteins to interact
with collagen has caused misinterpretation. This may explain why many receptors for
collagen have been found in association with haemostatic defects in patients with receptor
malfunctions or by autoantibodies against the receptor in question. During the past
years several receptor candidates have been put forward (reviewed in Table 1), but
new data have discarded many of the putative ones. Hence currently, only five direct
collagen receptors are considered to be important for platelet-collagen interaction: GPIa/
IIa, GPVI, GPIV, a 65 kDa and a 68 kDa proteins.
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Table 1. Putative and established* collagen receptors. Adapted from Chiang
199953.
3.1.1. GPIa/IIa
GPIa/IIa or integrin α
2
β
1
 (VLA-2, CD49b/CD29) receptor is a low-density platelet
receptor (800-3500 copies3; 158), which was originally found in a patient with a bleeding
diathesis showing poor aggregation, adhesion and spreading of platelets in response to
collagen225; 226. After determination of molecular weight (160 kDa) and magnesium
(Mg2+)-dependence of the collagen-binding receptor, GPIa was soon identified as a
part of the human T-cell very late antigen 2 and as the integrin α–chain of the α
2
β
1
complex185; 275; 276. Later additional patients have been described with either inhibitory
antibodies18; 77or other etiologies131; 170. Furthermore, small amounts of GPIa/IIa receptor
were found to critically influence severity of a haemostatic deficiency caused by an-
other platelet receptor18; 81.
Platelet α
2
β
1
 belongs to the integrin superfamily consisting of noncovalently linked α/β
heterodimers (150-165 kDa and 130 kDa). Integrins are a major group of the adhesive
cell receptors (18 α-and 8 β-subunits known today) mediating a number of matrix and
cell-interactions for different cell types (reviewed in127; 149). The ligand-specificity of
the integrins depends on the cell type so that α
2
β
1
 may also act as a receptor for
laminin, tenascin or echovirus-1, in addition to being a collagen receptor in platelets82.
Promiscuous adhesion activity has also been found in platelets327. The α
2
-subunit con-
tains a 200 amino acid I-domain situated on top of the so-called β-propeller domain,
which forms a doughnut-like ring on a transmembrane stem. The I-domain is essential
for cation-dependent ligand binding80; 163; 304, and a homologous I-like domain also ex-
ists in the β-subunit319. In addition, the EF-hand motifs of the α-chain contribute essen-
tially in the binding activity83. However, the inhibitory effect of Ca2+-ions on α
2
β
1
–
collagen binding was shown to be mediated by other parts of the integrin molecule than
Protein Method of isolation Comments
Glucosyl transferase 11 Enzyme substrate
Fibronectin 19 Binding, antibody Indirect binding via GPIIb/IIIa or a5b1
65 kDa protein* 54; 55 Affinity column, antibody Collagen type I specific
GPIIb/IIIa 62; 164; 287 Antibody Activation-dependent or indirect
binding via collagen associated plasma
proteins
vWf 144; 263 Binding indirect binding via GPIb, high shear
Factor XIII 269 Binding
61 kDa protein 178 Affinity column
GPIa/IIa* 91; 225; 304 Patient study Collagens type I-VIII,
GER-sequence
GPVI* (61-62kDa) 58; 302 Patient study, CRP-peptide GPP*-sequence, convulxin
GPIV* (88 kDa) 199; 305 Patient study, antibody
αvβ3 76 Antibody RGD-sequence in denatured collagen
85 kDa protein 78 Patient study
47 kDa protein 56 Affinity column, antibody Collagen type III-specific
68/72 kDa proteins* 209 Peptide Collagen type III-specific
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either I- or the EF-hand domains. Recently, a docking model of α
2
 I-domain and colla-
gen was formed based on the crystal structure and mutagenesis data91; 162. A snake
venom disintegrin-metalloproteinase peptide, RKK, from the viper Bothrops jararaca,
was found to inhibit collagen-I-domain interaction cation-dependently153. Different func-
tional states of α
2
β
1
 have been observed also affecting the ligand specificity278. Evi-
dence of affinity modulation in α
2
β
1
 suggests that cation- or ligand-binding can alter
the integrin-affinity for collagen123; 297. Exogenous ADP, thrombin, collagen-related
peptide (CRP) and an α
2
β
1
-activating antibody could also provide similar enhance-
ment in affinity158; 161.
GPIa/IIa is a universal collagen receptor, which mediates platelet adhesion to collagen
types I-VIII under blood flow conditions268. A twenty-fold difference in collagen ad-
hesion was correlated with blood donor-dependent variability in GPIa/IIa186. This was
subsequently related to allele-specific differences in receptor densities that regulated
the rate of platelet attachment to type I collagen under high shear-rate conditions181.
Recently, genetic variation of GPIa/IIa has been shown to associate with increased
risk of thrombotic complications46; 218; 279.
Integrins are known to form functional complexes with other molecules, which may
affect their function. These include intracellular proteins of cytoskeleton and of signal-
ling but also of membrane-integrated proteins (reviewed in246). Of these at least integrin-
associated protein (IAP, CD47) and members of the tetraspanin superfamily have
been found in platelets, and IAP has been shown to participate synergistically in GPIa/
IIa-mediated platelet activation by collagen57. In addition, platelet adhesion to collagen
was enhanced by gangliosides via an GPIa/IIa–mediated mechanism, suggesting that
these lipids may affect the integrin affinity through receptor clustering and signal-
ling334; 335.
3.1.2. GPIV
GPIV (CD36, GPIIIb), a highly glycosylated, protease-resistant and hydrophobic pro-
tein (88 kDa) belongs to a new and growing family of integral membrane proteins with
a wide range of ligands. GPIV is a receptor of many functions: adhesion to collagen
and thrombospondin in platelets and a scavenging receptor of malaria-infected red
cells, fatty acids and oxidised low-density lipoproteins in macrophages75. In literature,
the role of GPIV as a collagen receptor has been controversial, not least because most
studies of GPIV-deficient platelets with Naka- phenotype, present in 3% of Japanese
population, substantiate normal collagen-induced aggregation171; 344, adhesion under
both static and flow conditions202; 266, and finally undisturbed signal transduction73.
However, some of these studies did recognise an impaired platelet aggregation and
adhesion to collagen type V171; 266. Conversely, the group of Jamieson et al. found an
effect on platelet responses to collagen type I by using Naka-platelets84; 306. They fur-
ther corroborated these results with polyclonal and monoclonal antibodies against GPIV
and could demonstrate a role for GPIV in the early (2-5 min) phases of platelet-colla-
gen interaction under flowing blood in the absence of Mg2+ 85; 199.
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3.1.3. GPVI
Immunoglobulin superfamily member GPVI (p62) was recently cloned and found closely
related to natural killer receptors and Fcα-receptor58. Originally, this receptor was also
identified because of a mild bleeding problem in a patient. The patient’s platelets were
found to be refractory to collagen but not to other stimuli302. An autoantibody against a
62 kDa protein, lacking in the patient’s platelets, aggregates heterologous platelets.
The receptor number in platelets is currently unknown although convulxin (CVX), a
snake venom protein from Crotalus durissicus terrificus and a known ligand of GPVI,
has been shown to occupy 100-460 high affinity binding sites in platelets157. Another
GPVI-recognising ligand is the synthetic CRP-peptide213, which specifically interacts
and activates platelets through GPVI176.
GPVI is an important receptor mediating collagen-induced platelet activation and ag-
gregation172, and it has been called as the main collagen signalling molecule in platelets,
challenging the influence of α
2
β
1
331(see chapter 4). Stationary adhesion experiments
have implicated a role for a cation-independent receptor in platelet attachment to fibril-
lar collagen215; 349. However, by the use of CRP in adhesion and flow studies, GPVI
was shown to be incapable of mediating platelet attachment under conditions of blood
flow, even at low shear rates326, in contrast to stationary adhesion213. Accordingly,
biphasic platelet deposition to collagen type III was affected only at the level of aggre-
gate formation, but not at the level of initial surface coverage in a study using citrate-
anticoagulated GPVI-deficient blood211.
3.1.4. 65 and 68/72 kDa collagen receptors
Despite the multitude of collagen receptor candidates in platelets, most of the findings
in Table 1 have been left as single observations without further confirmation. In addi-
tion to the more established receptors GPIa/IIa, IV and VI, analysis of two other
receptor candidates has been carried out further. The type I collagen-specific 65 kDa
receptor has been cloned and it does not share homology with any other known
receptor55. The 65 kDa -receptor was shown to be capable of mediating phosphoinositide
hydrolysis, calcium mobilisation and furthermore, it co-precipitated with protein phos-
phatase 153.
Type III collagen-specific receptor was originally recognised using a synthetic oc-
tapeptide166; 209. This peptide was found to associate with to two different proteins, 68
and 72 kDa, in ligand blotting after SDS-PAGE.  The octapeptide inhibited platelet
interaction to both type III collagen and subendothelium, and platelet adhesion-induced
activation of several signalling molecules. However, the relationship of these two
receptors with the other established receptors as well as their position in the sequential
collagen adhesion events in platelets remain to be determined.
3.2. Blood flow-mediated effects on platelet-collagen interaction
In vivo platelet interaction with collagen is influenced by the shear forces of flowing
blood124. Shear rate depends on the size of the vessel, the flow rate and the viscosity
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mainly affected by the red cell content of the blood. The shear rates vary between 30-
50 s-1 in large veins and 200-500 s-1 in aorta and 500-10000 s-1 in smaller arterioles320.
In stenosed atherosclerotic coronary arteries, shear rates of 3000-10000 s-1 have been
measured at the top of plaques, depending on the severity of the stenosis262. Because
of the local shear rate, platelets contribute significantly more in arterial than in venous
thrombus formation, whereas fibrin formation negatively correlates with shear forces333.
The plasma protein fibrinogen affects the shear rate by influencing blood viscosity, but
other plasma proteins also participate in platelet attachment to collagen as molecules
capable of interacting with collagen and thus bridging it to platelets via specific receptors,
e.g. GPIIb/IIIa. Such proteins include vWf, fibronectin and thrombospondin. In addi-
tion to plasma, these proteins are also present in platelet secretory granules, and can be
liberated upon platelet activation. Finally, vWf and fibronectin reside in vessel matrix
as well. While fibrin is not a component of the normal vessel wall, increasing amounts
of fibrinogen and fibrin incorporate in intima during atherosclerosis thus increasing the
thrombogenicity of the subendothelium322.  The influence of these proteins on platelet
interaction with collagen is shear rate-dependent: above shear rates 1500 s-1 adhesion
completely depends on vWf-GPIb/V/IX-interaction, whereas fibrinogen and fibronectin
play a role at lower shear rates.
3.3. Role of von Willebrand factor
Interaction between vWf and subendothelial collagens varies, being different for type
IV, VI and the fibrillar collagens293. Divalent cation-independence of vWf binding to
collagens I and III has been verified by elucidation of the crystal structure30; 147. The
A3-domain of vWf contains a metal ion-dependent adhesion-site (MIDAS)-domain
that is defective in cation-binding. Instead, the flat binding surface engages in electro-
static interactions between the negative charges of vWf and positive charges on the
collagen molecule. As already mentioned above, the participation of the GPIb-vWf
axis in platelet collagen-interaction becomes indispensable at shear rates over 1500 s-
1, tethering the platelets along the surface and making irreversible adhesion possible
through collagen receptors and GPIIb/IIIa282. This function is analogous with the selectin-
mediated leukocyte rolling along activated endothelium. Recently, the role of vWf and
fibrinogen under various shear rates was re-evaluated demonstrating the involvement
of both molecules in thrombus formation over collagen type I. The concept of vWf
operating only under high shear rate conditions was revised by the demonstration of
decreased thrombus height and volume in the absence of functional GPIb under shear
rate of 300 s-1 264. Vice versa, in addition to low shear-rate conditions, fibrinogen-
dependent stabilisation of thrombi was shown to be essential under high shear-rate264;
316. The amount of GPIb can be decreased by 50% before platelet adhesion to colla-
gen under high shear rates is affected323. GPIb-vWf interaction has been shown to
activate GPIIb/IIIa via the 14-3-3 proteins, homologous of cPLA
2
. However, the sig-
nificance of GPIb-induced signal transduction in platelet-collagen interaction is still
uncovered97; 187.
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3.4. Collagen sequences relevant for platelet interaction
In the beginning of the search for the platelet reactive sites in collagens, adhesion and
aggregation techniques were used to evaluate the interaction. Despite the crude meth-
ods, the importance of the collagen tertiary versus quaternary structure was fairly
early recognised in platelet activation and aggregation38; 156; 220. Subsequently, the ad-
hesion sites in collagens I and III were targeted with cyanogen bromide-generated
peptides of separate α-chains212; 215; 267; 298; 348. These studies indicated the existence
of several α
2
β
1
-binding sites in collagen type I. A homologous site was found in both
α1(I)CB3- and α1(III)CB4-fragments at the same amino acid range (403-551) of the
parent molecules. Interestingly, when compared with each other, the platelet-reactivity
of the fragments varied, suggestive of multiple collagen receptors in platelets with
specialised functions215. Later the binding of a specific collagen receptor to α1(I)CB3-
fragment was verified under flow, while other fragments, 7 and 8, were discovered to
be important in vWf-mediated platelet-collagen interaction267.
The first inhibition studies using α1(I)CB3-fragment derived linear peptides lead to
identification of an aspartate–glycine-glutamate-alanine (DGEA) -sequence (435-438)
as the recognition motif in collagen296, and KDGEA peptide at high concentrations
was shown to influence GPIa/IIa -mediated signalling in platelets168. However, in a
recent study, no adhesion was observed to the DGEA-sequence, but a glycine-gluta-
mate-arginine (GER) –sequence, provided in a triple-helical peptide form, was shown
to be essential in the platelet-binding to type I collagen via GPIa/IIa177. The authors
found the E and R residues necessary for the activity, which closely resemble the D-
and R-residues in the α
1
β
1
-binding site of collagen type IV89. Crystal structure studies
of the I-domain have recently modelled a Mg2+-binding E-residue essential in the col-
lagen molecule91. Collagen type I contains also a universal integrin recognition site of
arginine-glycine-aspartate, RGD, which, however, is normally cryptic. RGD-sequence
might become important for adhesion when the native collagen structure is disturbed
(reviewed in318). Moreover, it has been reported that a cyclic-form of RGD peptide is
capable of interacting with α
2
β
1
45.
Advancement in characterisation of functional determinants was made with the syn-
thesis of collagen-derived peptides based on collagen structures166; 253; 261. By intro-
ducing GPP*-triplets in the end of one of these sequences (KPGEPGPK), Morton et
al could induce platelet aggregation214. This lead to the synthesis and analysis of colla-
gen related-peptide, (CRP), a cross-linked form of glycine-cysteine-hydroxyproline-
(GPP*)
10
-glycine-cysteine-hydroxyproline-glycine213. CRP conclusively established the
existence of α
2
β
1
-independent platelet-collagen reactivity in the collagen molecule and
its dependence on tertiary (triple-helical) and quaternary (polymeric) protein folding.
Comparison studies of CRP with monomeric CRP illustrated the potency of multiple
cross-linking in the collagen-induced activation7. The current view of platelet-collagen
adhesion mechanisms based on the peptides suggests that three mechanisms occur:
two-cation-dependent, one of which is α
2
β
1
-independent and a third, cation-and α
2
β
1
-
independent mechanism. Minimal sequence required for α
2
β
1
-recognition was pro-
posed to be GGPP*GPR by analysing overlapping peptides from α1(III)CB4, whereas
the GPVI recognises the basic triple-helix, and the activatory function of this determi-
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nant can be enhanced or inhibited by additional sequences216.
3.5. Two-site two-step model
The sequential nature of events and true functions of certain receptors in platelet-
collagen interaction were not revealed until in vitro perfusion experiments with whole
blood became a practice17. Currently, platelet interaction with collagen is considered to
be a stepwise reaction of two receptors, α
2
β
1
 and GPVI13; 59; 210; 293. These receptors,
as mentioned above, associate with different determinants on the collagen molecule
and following GPIb-vWf-mediated tethering, firmly attach and activate platelets lead-
ing to GPIIb/IIIa-mediated thrombus formation. In this so-called two-site two-step
model, platelets adhere first to specific sites on the collagen molecule via α
2
β
1
 and
subsequently become activated through GPVI-interaction with the sequences provided
by the quaternary structure of the collagen fibril (Figure 5). This model arose fairly
early when analysis of platelet-collagen interaction revealed that some sites of colla-
gen mediated only adhesion whereas others were platelet-aggregatory215; 277. Although
the actual binding and activating sites in collagen suggested by the original models
differ from the ones currently considered important, already then it was established
that the first adhesive site was Mg2+-dependent and likely to be α
2
β
1
, and the second
low-affinity site responsible for activation was cation-independent. However, this model
does not contain all the currently recognised collagen receptors, and furthermore, the
interplay between these receptors remains to be elucidated. One important way to do
this is to investigate receptors responsible for collagen adhesion-mediated platelet-
activation.
Figure 5. Current two-site two-step model of platelet-collagen interaction dem-
onstrating the roles of the adhesive and activating receptors, GPIa/IIa and
GPVI, respectively. Adapted from Barnes et al 199813.
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4. COLLAGEN-INDUCED SIGNALLING IN PLATELETS
Collagen is a unique platelet agonist since it acts both as an adhesive surface and as a
strong activator. Collagen-induced signal transduction in platelets leads to the activa-
tion of GPIIb/IIIa, formation of TXA
2
, secretion of enhancing activators like ADP
upon the release of α- and dense granules, and formation of the procoagulant phos-
pholipid surface. The downstream mediators following PLCγ are 1,2-diacylglycerol-
activated PKC and inositol (1,4,5)-trisphosphate-liberated Ca2+. In turn these molecules
engage other signal transduction pathways. In contrast with G-protein-activated PLCβ,
the tyrosine kinase-based activation of PLCγ2, the main isoform in platelets, is central
for collagen-induced activation in addition to other signalling molecules such as Btk330.
It has become accepted that GPVI is responsible for the majority of signalling events,
but a large body of evidence demonstrates that it is not the sole effector. A simplified
review of GPVI-mediated collagen-induced signal transduction is presented below
with evidence for other participating receptors (see also Figure 6).
4.1. Signalling through GPVI
Like platelet integrins, also GPVI receptor has only a short cytoplasmic tail devoid of
recognisable signalling domains. Thus, it must form complexes with other molecules to
mediate signal transduction. GPVI on the platelet membrane associates with 14 kDa
γ-chain of the immunoglobulin receptor (FcRγ) that mediates signals through its
immunoreceptor tyrosine-based activation motif (ITAM)121; 315. Upon tyrosine phos-
phorylation of the ITAM-domain, a cytosolic tyrosine kinase, Syk, is recruited to the
complex via its Src-homology (SH2)-domains leading to its activation by
autophosphorylation and Src-phosphorylation. Syk will then activate PLCγ2. Syk has
also been reported to become tyrosine-phosphorylated and activated by other platelet
agonists like thrombin, ADP, TxA2, and also by engagement of FcγRIIA, GPIIb/IIIa-
fibrinogen-, and GPIb-vWf interaction, although the necessity of Syk-mediated signal-
ling for these stimuli has also been questioned191. The validity of this model in collagen-
induced activation is demonstrated by the proportional absence of both FcRγ and GPVI
in GPVI-deficient platelets with impaired collagen signalling, and by the total absence
of PLCγ2−phosphorylation and collagen-induced platelet activation in FcγR- and Syk-
knock-out mice245; 315. Furthermore, specific GPVI-activating ligands such as CRP
and CVX induce phosphorylation of FcγR, Syk and PLCγ2 6; 244. Phosphorylation of
the ITAM-motif by collagen activation is postulated to occur through Src-family kinases
Fyn and Lyn, but how they become activated remains unclear41; 96. However, despite
the phosphorylation of PLCγ2, aggregation, secretion, phosphoinositide- and Ca2+-sig-
nal generation in CVX-activated platelets were abolished with a tyrosine phosphatase
inhibitor, and partially decreased by inhibition of phosphoinositide 3(PI3)-kinase189, sug-
gesting that Syk-mediated activation of PLCγ2 might not be enough for the full re-
sponse. PI3-kinase-mediated pathway produces 3’phosphorylated phosphatidylinositol
trisphosphates, which are able to activate other kinase pathways such as protein ki-
nase B/Akt and c-Jun NH2-terminal (JNK) kinase of the mitogen-activated (MAP)
kinase family through their pleckstrin homology -domains10. The 3’ phosphorylated
lipid-mediated activation probably also allows the lipase to associate with the plasma
membrane.
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The signal pathways downstream of Syk are not currently clear. Numerous kinases
such as Bruton’s tyrosine kinase (Btk)250, adapter proteins such as LAT and SLP-76
and also other pathways from agonists like thrombin come into play, interacting with
each other quite early in the platelet activation process. Although the exact sequence
of events is not known, some relevant participants have been recognised. Platelet
signalling pathway-models have been postulated because of the parallels with
immunoreceptor–based activation events in T-cells.
Phosphorylation of the transmembrane adapter protein LAT by a Syk-family kinase
has been shown in T-cells and similar pathways are suggested to work also in platelets
during collagen-induced signal transduction347. PI3-kinase was shown to associate with
both phosphorylated FcγR and LAT in collagen- and CVX-activated platelets120. Fur-
thermore, in addition to PLCγ2, growth receptor binding protein (Grb) 2 associates
with LAT, leading to the involvement of the extracellular signal-regulated kinase (ERK)
MAP-kinase route. Another adapter protein specific for collagen activation in platelets
is the T-cell adapter protein SLP-76. Although the precise role of SLP-76 in collagen
induced activation is unknown, a few clues are given by the facts that only collagen,
but not thrombin, responses are blocked in mice deficient in SLP-76, and collagen- and
CRP-responses such as Ca2+-mobilisation, PLCγ2-phosphorylation and platelet aggre-
gation are dampened accordingly330. In T-cells SLP-76 binds Grb2 and could thus
mediate the activation of MAP kinases through GTP-exchange factors such as Vav,
which is suggested to be involved in the activation of p38 MAPK330.
As mentioned earlier, PLCγ2−activation induces elevation of cytosolic Ca2+ and acti-
vation of PKC. The Ca2+-signal induced by collagen activation is very essential, as can
be shown with intracellular Ca2+-chelators. The elevation of Ca2+ regulates cPLA2,
and its activity can be further increased by dual phosphorylation. The kinase responsi-
ble for this has been proposed to be p38 MAPK and other kinases downstream from
it330. However, contradictory reports have been published concerning the role of the
p38 MAPK inhibition on AA-release and TxB
2
-formation36; 128; 180; 272.
P38 MAPK may be otherwise involved in collagen-induced platelet activation. A spe-
cific inhibitor, SB203580, could inhibit collagen-induced platelet aggregation272. P38
MAPK activates other kinases resulting in phosphorylation of heat-shock protein 27, a
regulator of cytoskeletal actin assembly148; 272. There are three different pathways of
MAPKs, which belong to two different general activation pathways, the growth fac-
tor- or the stress-activated MAPKs. The ERK-pathway belongs to the first, whereas
JNK- and p38 MAPKs belong to the latter group90. MAPKs form kinase-cascade
modules that associate with specific scaffold proteins and other signalling proteins in
specific parts of cells or substrates. MAPKs are involved in cell division, differentia-
tion and controlled cell death (apoptosis) in response to various extracellular stimuli
from growth factors to stress-inducing agents. The significance of p38 MAPK in col-
lagen-induced platelet activation is unclear. In other cells p38 MAPK has a role in
inflammation, apoptosis and in cell growth224. In Btk-deficient mice both JNK- and to
a lesser extent p38 MAPK -activities were disturbed and their mast cells were pro-
tected from apoptosis167. Several other apoptosis-related observations of p38 MAPK
function have been made22; 31; 224.
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4.2. Signalling through other collagen-receptors
The strongest evidence for the role of other platelet receptors in collagen-induced
platelet activation originates from studies with GPVI-deficient platelets. In response to
collagen challenge, they exhibit weak, but clear tyrosine phosphorylation and activation
of GPIIb/IIIa capable of fibrinogen engagement150; 172; 222. Strongest candidate as a
signalling molecule is the α
2
β
1
-integrin responsible for significant signalling in other
cells. Integrin-mediated signalling has been shown to involve focal adhesion kinase
(FAK) and focal adhesion complexes around it48. These signals usually depend on the
β-chain of the integrin164; 343, but recently, α
2
-chain was also shown to activate p38
MAPK154. However, α
2
β
1
 or GPIa/IIa-mediated signalling in platelets may differ from
that in nucleated cells as illustrated by the differences in Ca2+-mobilisation between
megakaryocytes and mature platelets40.
Difficult estimation of the role of GPIa/IIa in platelet signalling arises from differences
in experimental set-ups. Monoclonal antibodies inhibit signalling through impairing platelet-
collagen interaction and not necessarily by inhibiting receptor-mediated signalling per
se. Moreover, receptor interplay and the activation of GPIa/IIa may be difficult to
consider. Collagen-induced signalling via GPIa/IIa was shown to involve FAK-phos-
phorylation before platelet spreading under flow conditions241 and also when platelets
staticly adhered on collagen129. In contrast, FAK was not phosphorylated by soluble
collagen196. GPIa/IIa mediated signals have been shown to be dependent on the cy-
toskeleton, in agreement with its role in adhesion and spreading5; 152. Adhesion to salt-
soluble collagen caused significant dephosphorylation of several bands that were highly
phosphorylated in resting platelets and inhibition of the phosphatase activity led to de-
creased adhesion243. In addition, adhesion was dependent on dephosphorylation of a
heat-shock complex 70, a complex consisting of heat shock proteins 70 and 90 and
protein phosphatase 1 subunits. The inhibitory role for GPIa/IIa–mediated signalling
has also been suggested by others330. GPVI-signals shared with GPIa/IIa include in-
creases in [Ca2+]
i
5; 152, activation of PKC164; 243, and tyrosine phosphorylation of pro-
teins such as Syk and PLCγ2164; 168. In contrast, only GPIa/IIa mediates cytoskeleton-
dependent phosphorylation106; 152. Moreover, collagen-induced platelet adenylate cy-
clase inhibition was found to be GPVI-independent1. Conversely, GPVI-deficient plate-
lets were found incapable of Syk- and PLCγ2-phosphorylation, whereas c-Src re-
mained active until GPIa/IIa was inhibited150. Furthermore, a GPIa/IIa binding-peptide
containing the GER-sequence and supporting adhesion as efficiently as collagen, was
unable to induce detectable tyrosine phosphorylation or platelet aggregation176. It is
thus possible that one or more of the several other collagen-receptors participate in
collagen-induced signalling. GPIV was shown to associate with Src-family kinases
Fyn, Lyn and Yes86; 145. Src-kinases as well as GPIV itself, are postulated to function
in the early phases of platelet-interaction. However, GPIV-deficient platelets from a
Naka-negative donor showed normal intracellular calcium mobilisation and tyrosine
phosphorylation, suggesting that GPIV is unlikely to play any major role in collagen-
induced signalling73. The newly characterised platelet-collagen receptors were shown
to be able to induce signal transduction in platelets, but their signalling role and place
regarding GPIa/IIa and GPVI need to be elucidated55 209.
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Figure 6. Collagen-induced signal transduction in platelets. A schematic pres-
entation summarises the pathways known or proposed to be mediated by dif-
ferent receptors according  to current literature. In addition, collagen-induced
signaling is presented in possible relation with microvesiculation. Pathways
described only in other cells than platelets are shown with a dashed line.
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5. PLATELET-DERIVED MICROPARTICLES
Membrane vesiculation associated with loss of lipid asymmetry is a general feature in
many cells during physiological and pathophysiological events. Cells undergoing pro-
grammed-cell-death, apoptosis49, tumorigenic cells88, inflamed or otherwise activated
endothelial cells64; 130, sickled erythrocytes108 and tissue factor-expressing monocytes280
are but a few examples. However, shedding of procoagulant microparticles (MP) or
microvesicles from these cells is considered to be less efficient than from platelets281.
5.1. What are microparticles?
Platelet-derived MP are submicroscopic vesicles of heterogeneous size carrying abun-
dant negatively charged aminophospholipids after their formation from platelet plasma
membrane upon activation. Taking into account the minimal thickness of a lipid bilayer,
it has been calculated that the smallest size of MP would be 20 nm in diameter. Obser-
vations of MP ranging from 70 nm up to 0.6 µm, a mini-platelet, have been made143;
274. MP surfaces contain essentially the activated platelet surface molecules, such as
membrane glycoproteins GPIIb/IIIa and GPIb/V/IX and P-selectin. Some molecules,
like protein S72, GPIIb/IIIa and binding sites for factors V and VIII, were also found to
be enriched in MP in comparison with platelets122; 292. However, MP are a heterogene-
ous population dependent on the generative agonist229; 292, not only sizewise but also in
their surface molecules: 73% of MP labelled with a lipophilic dye were detected with
an antibody against GPIIb/IIIa, but only 43% of these MP were recognised with a
GPIb-antibody33.
5.2. Properties and function of microparticles
During the 1940s, clotting time was found to be shortened by the addition of serum or
platelet-poor plasma, but in 1967, Wolf identified this capacity to “platelet dust”, small
membrane fragments originating from platelets when activated or stored for a longer
time periods342. For a while this activity was called platelet factor 3 of the coagulation
cascade, covering both MP and the negatively charged platelet surface. Microparticles
have been detected in vivo in association with several pathological states of increased
coagulation and thrombosis, and the specific disorders of MP generation (Scott’s syn-
drome and Casteman’s disorder) have been associated with bleeding (reviewed in 143).
However, at least in vitro the same MP-surface also functions as a site of anticoagu-
lant activities and an “inverse Scott’s syndrome” patient that spontaneously expresses
PS and microvesiculates, surprisingly displays a bleeding tendency300. Hence, the role
of MP in coagulation is not clear-cut.
Low levels of circulating MP are considered to participate in maintaining normal hae-
mostasis20; 342. Recently, when the cross-talk between different cell populations has
been actively studied, increasing interest has also been focused on other possible roles
for platelet-derived MP. Many of these proposed functions have only been investi-
gated in vitro, while some of the putative ones are based on the molecules provided by
MP (summarised in Table II). Thus, more research is clearly needed to establish the
effects and significance of MP.
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5.3. Generation of microparticles
The capacity of a range of platelet agonists to induce MP formation has been thor-
oughly investigated. Although the results of quantitative comparisons on agonist effi-
ciency heavily depend on the method of analysis, several in vitro studies have estab-
lished a qualitative order of potency for different MP-forming activators, A23187 cal-
cium ionophore > C5b9-membrane attack complex of the complement system > thrombin
and collagen co-stimulation > thrombin or collagen > epinephrine or ADP143. In addi-
tion, mechanic stimuli such as artificial surfaces115 or high shear stress were found to
induce MP formation in a perfusion model139; 207; 270. Furthermore, freeze-thawing,
phosphatidyl choline-vesicles and complement-independent platelet activation by CD9-
antibodies were effective generators of MP27; 231. In all, MP can be induced in several
ways, but the most physiological ways are thrombin and collagen co-stimulation, acti-
vation by complement and pathologically high shear rates.
Although microvesiculation and the loss of membrane asymmetry are closely associ-
ated51, they can still be considered as separate activation events, as was evidenced by
certain Ca2+-ATPase inhibitors, which induced selective increases in internal Ca2+-
concentration70, by use of heavy-metal compounds125, and by platelets from a disorder
exhibiting solely impairment of microvesiculation but not of aminophospholipid expo-
sure50. Moreover, in a high-shear-induced activation model, the annexin V-binding site
exposure occurred faster than the formation of MP 270. On the other hand, a reversed
state, in which MP are shed without concurrent aminophospholipid-exposure on the
remnant cells, was only observed in C5b-9-activated platelets and in sickled erythro-
cytes352. In both cases, the translocase enzyme was claimed to remain active and to
eliminate PS and PE from the outer leaflet. However, as a rule, microvesiculation only
function or role ref. molecule on MP
assembly of coagulation complexes
and generation of thrombin
227; 352 PS, PE, factor Va, VIIIa, IXa, PCI
anticoagulation 72; 230;
307
APC, protein S, PCI,
amyloid β-protein precursor
activation of neutrophils and monocytes,
monocyte chemotaxis and interaction with
endothelium, atherogenesis
14; 16;
159; 206
P-selectin, AA
synthesis of PGI2 in endothelial cells 15 AA
foam cell formation 197 whole MP
cell aggregation and activation 101; 155 PAF, LPA
use as a platelet substitute 52; 201 whole MP
platelet adhesion to subendothelium 203 GPIIb/IIIa
generation of LPA 101 phospholipids (by secretory PLA2)
tumour metastasis 238 whole MP
antiphospholipid antibody-mediated coagulation 
atherogenesis
114; 252
117
β2-glycoprotein I
inflammation 119; 239;
291
C1q receptor, P-selectin
β2-glycoprotein I
Table 2. Summary of possible effector functions of platelet-derived-MP
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occurs after the exposure of negatively charged aminophospholipids.
So far, very little is known of signal transduction responsible for microvesiculation.
MP-generation has been shown to be independent of platelet aggregation and granule
secretion. Thus, it represents a distinct platelet activation event, which is impaired by
intracellular increases in cyclic nucleotides affecting both platelet annexin V-binding
and MP generation309; 338. Next, I will review the literature on signal transduction specu-
lated to be relevant for MP formation, i.e. Ca2+-signal, protease activation, protein
phosphorylation and the role of GPIIb/IIIa.
5.3.1. Intracellular Ca2+
The activity of translocase depends on the concentration of intraplatelet Ca2+, as dis-
cussed earlier in the thesis (chapter 1.3.). The consensus has long been that the most
important signal in microvesiculation is the increased intraplatelet Ca2+-concentration291;
337, and it was recently verified that the platelets with high intracellular Ca2+ were
indeed the MP-forming species71; 134. Different internal Ca2+-concentrations obtained
with Ca2+-ATPase inhibitors dissociated the expression of prothrombotic catalytic sur-
face as a separate activation event from microvesiculation70. Furthermore, different
amounts of MP were shown to be generated at the same intracellular Ca2+-level,
suggesting the importance of additional signals in effective MP formation295. This has
been interpreted to depend on Ca2+-influx, further supported by the fact that calcium
ionophore  was unable to generate MP in the absence of extracellular Ca2+, although it
is able to release Ca2+ from the intracellular stores236. Also, sole incubation of platelets
in 10 mM external Ca2+-concentration for 2 hours resulted in formation of MP314. One
consequence of the rise in internal [Ca2+] relevant for microvesiculation is the activa-
tion of a ubiquitous calcium-activated neutral protease, calpain. Two forms of calpain,
µ and m, with different activation requirements of Ca2+, reside in platelets317. Calpain
activation in calcium ionophore-stimulated platelets occurred when internal Ca2+-con-
centration reached 3-8 µM, which coincides with the lower range needed for the
activation of membrane-associated calpain236.
 5.3.2.  Activation of proteases
MP-formation requires extensive cytoskeletal changes in platelets. Cytochalasin D,
which inhibits actin polymerisation, almost completely abolishes microvesiculation113;
345. The role of calpain-mediated hydrolysis as a prerequisite for microvesiculation is
enigmatic. The activation of calpain is Ca2+-influx-dependent, and the subsequent hy-
drolysis of cytoskeletal connections has been considered essential in allowing vesiculation
after the excessive incorporation of aminophospholipids on the external surface of
platelet plasma membrane113; 236. Furthermore, active calpain has been shown to in-
corporate into the shed microparticles 238. However, whereas MP-formation clearly
increased with calpain-mediated hydrolysis of the actin-membrane interactions induced
by other agonist103, Sims et al detected no effect of calpain inhibition on microvesiculation
induced by C5b-9104; 337. The observed differences were partly explained by a study
establishing a role for calpain in the early formation of MP, while calpain inhibitors had
no effect at 30-min timepoint. Also, the particular agonist, the inhibitor and their con-
centrations may cause the observed differences346. However, despite the fact that
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inhibition of calpain prevents platelets from microvesiculating in response to certain
stimuli, the absolute necessity for calpain was also questioned by normal, agonist-
independent activation of calpain in Scott’s syndrome platelets69, in addition to ineffec-
tiveness of calpain inhibitors on C5b9- or calcium ionophore-induced microvesiculation337.
In an early study, the restoration of translocase activity was shown to depend on inhi-
bition of calpain, implying that calpain activation hinders translocase- and not the
“scramblase”-like activity65. Hence it is possible that calpain activity is not necessary
for agonists that generate direct Ca2+-influx by themselves, i.e., calcium ionophore and
C5b-9. Another possible microvesiculation-related signalling pathway was indicated
by a study demonstrating the importance of protein phosphorylation-dependent
cytoskeletal reorganisation for MP-induction345.
Also recently, biochemical and morphological features common to platelet activation
and apoptosis led to the discovery of caspases 3, 9 and caspase activators and inhibi-
tors in platelets290; 324; 341. Caspases, cysteine proteases, are involved in the initial sig-
nalling events and the downstream proteolytic cleavages that result in the apoptotic
phenotype in cells. Caspase 3 is an effector protease responsible, for instance, for the
degradation of cytoskeletal proteins such as actin and fodrin310. A contradictory role of
caspases in microvesiculation was found in the two recent studies. In the first study by
Shcherbina & Remold-O’Donnel, caspase 3 was found to become activated by com-
mon MP-inducing agonists, and the order of caspase-activating potency coincided with
the MP-inducing potency of the agonist290. Inhibition of caspase 3 impaired both PS-
exposure and microvesiculation, whereas calpain inhibition blocked only
microvesiculation suggesting that caspase might activate PS exposure whereas calpain
could terminate it. In contrast, Wolf et al found no activation of caspases by thrombin
and collagen co-stimulation341. Furthermore, they showed that instead of caspases,
calpain became activated during platelet stimulation and in vitro calpain could cleave
caspases into a non-active form. The authors concluded that the presence of caspases
in platelets was either coincidental or possibly anti-apoptotic. Further studies are re-
quired to clarify the interplay between calpain and caspases and their role in
microvesiculation, since some of its morphological and functional aspects are reminis-
cent of those in apoptosis.
5.3.3. Protein phosphorylation
Protein phosphorylation regulates intracellular activation and inactivation of proteins
and lipids. It is a dynamic and reversible process depending as much on the phospho-
rylating kinases as on the dephosphorylating phosphatases195. Both serine and threo-
nine kinases such as PKC and tyrosine kinases have been implicated in the regulation
of platelet derived-MP generation.
Inhibitors of PKC decreased thrombin- and- collagen- but not A23187-induced annexin
V-binding to platelets309, and serine/threonine phosphatase inhibitors such as calyculin
A and okadaic acid were found to increase the formation of MP345. In accordance
with the ionophore-induced MP formation, only a very small effect for PKC/tyrosine
kinase inhibitor, staurosporine, was found on C5b9-induced vesiculation338. Instead,
inhibitors of the myosin light chain kinase (MLCK) and the calmodulin-regulated kinases
impaired the ionophore-induced MP-generation. When challenged with thrombin and
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collagen co-stimulation, Scott’s syndrome platelets displayed abnormal tyrosine phos-
phorylation of 40, 97 and 116 kDa proteins69. This accords with observations that
collagen-induced microvesiculation is impaired by tyrosine kinase inhibitors, such as
genistein or high doses of wortmannin, which inhibits the PI3-kinase signalling path-
way134. Furthermore, orthovanadate, a tyrosine phosphatase inhibitor, increased com-
plement-induced MP accumulation by 40%338. Like PKC inhibitors, also tyrosine ki-
nase inhibitors did not hinder calcium ionophore-stimulated MP-formation134, but tyro-
sine phosphatase inhibitors did, although they concomitantly induced PS-exposure237.
From this the authors proposed a model in which tyrosine phosphorylation initiates PS
exposure, whereas activation of tyrosine dephosphorylation is needed for MP-forma-
tion, coinciding with the appearance of a 190 kDa tyrosine-phosphorylated protein and
activation of µ-calpain237. In summary, these data suggest that the state of intracellular
phosphorylation might regulate microvesiculation via the appropriate Ca2+-signal. Stimu-
lation with agonists that directly generate Ca2+-metabolism or -influx might work inde-
pendently of protein phosphorylation in contrast to agonists like collagen, which re-
quires tyrosine phosphorylation for Ca2+-mobilization. In support of this, tyrosine ki-
nase inhibitors were found to change the pattern of collagen-induced Ca2+-response
from a continuous elevation of Ca2+ into spikes134. Finally, the various MP-generating
pathways would be united in the requirement of timely and co-ordinated tyrosine de-
phosphorylation.
5.3.4. Role of GPIIb/IIIa
The role of GPIIb/IIIa in microvesiculation is dependent on the generative agonist.
Hence inhibition of GPIIb/IIIa prevented the thrombin- and collagen- or their co-stimu-
lation-induced MP-formation116; 229; 255, whereas it had no effect on calcium ionophore-
or complement-induced microvesiculation140 and only slightly decreased the high-shear
rate- or anti-CD9 antibody-induced activation207; 231. Most of these studies were sup-
ported by similar findings in Glanzmann’s thrombastenia patients lacking GPIIb/IIIa.
One putative role for GPIIb/IIIa has been suggested as a calcium channel109; 265. Inter-
estingly, ticlopidine, an ADP-receptor antagonist, was found to block Ca2+-influx via
GPIIb/IIIa, and simultaneously inhibit anti-CD9- induced microvesiculation231. ADP
has been shown to participate in the generation of sustained Ca2+-signal necessary for
procoagulant activity332. Thus it is plausible that GPIIb/IIIa may effect the generation
of MP by enhancing the rise of intracellular Ca2+. In addition, ligand binding of GPIIb/
IIIa has been shown to activate calpain105. However, the cytosolic domains of GPIIb/
IIIa molecule associate with many signalling molecules that may also otherwise induce
signal transduction relevant for micro-vesiculation289.
As a summary, the role of different signal transduction pathways in the generation of
MP is unclear. The signalling requirements are determined by the MP-generating ago-
nist and are likely to involve Ca2+-mobilization and regulation of kinases and phosphatases
and cytoskeletal regulation.
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Aims of the study
Despite intensive research on platelet-collagen interactions, the role of collagen struc-
ture and of different participating receptors in the platelet responses has only started
to become unravelled. Whole blood perfusion technique, in which the sequence of
adhesion-activation events can be studied under in vivo-mimicking conditions, has
provided a useful tool in elucidating relevant mechanisms. Utilising this technique
among others, the scope of this thesis has been to study platelet adhesion to type I
collagen and adhesion-dependent activation events culminating in platelet
microvesiculation. Specifically, the following aims were set:
• to investigate the effects of native collagen type I fibrils and their
proteolytically modified derivative on platelet functions
• to observe the formation of platelet-derived microparticles under conditions
of flowing whole blood in vitro and in vivo and to study their characteristics
• to elucidate specific mechanisms relevant for the collagen-induced
microparticle generation
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Materials and methods
Sources of antibodies and related materials (I-IV)
Collagens (I, II and III)
Native-type collagen I fibrils were extracted from bovine Achilles’ tendon fresh from
the slaughterhouse with 0.5 M acetic acid for at least over-night. Insoluble material
was removed by low-speed centrifugation and the fibrils were precipitated with 1.7 M
NaCl and suspended into 0.5 M acetic acid (designated NC)205. To obtain monomeric
collagen devoid of quaternary structure and telopeptides, NC was extensively treated
with pepsin during three weeks at +4°C, and salt-precipitated twice, then suspended in
0.5M acetic acid (designated PC). After high-speed centrifugation, only 2% of NC,
while over 90% of PC remained in the supernatant. Collagen concentrations were
determined by a modified hydroxyproline assay 175or using Sircoll dye from Biocolor
Ltd. Collagenreagent Horm was purchased from Nycomed Arzneimittel.
6F1 (anti-α2)*  
7E3 (anti-β 3)*
Dr. B. Coller, Mount Sinai Hospital, New York, USA
131.7 (anti-GPIV)* Dr. N. N. Tandon, Otsuka America Pharmaceutical,
Inc. Rockville, Maryland, USA
anti-GPVI antibody plasma
from a patient 302**
Dr. H. Takayama, Kyoto University, Japan
SAK-7 (anti-p38 rabbit serum)* Dr. J. Saklatvala, Kennedy Institute of Rheumatology,
London, UK
4G10 (anti-phosphotyrosine) Upstate Biotechnology
SZ22 (anti-αIIb)
Gi9 (anti-α2)
SZ2 (anti-GPIb) 
Immunotech S.A.
CLB-6 (anti-CD62) Netherlands Red Cross Blood Transfusion Service
T2G1 New York Blood Center
X63 American Type Culture Collection
AN51 (anti-Ib)
HRP-anti-human vWf
HRP-goat anti-mouse
TRITC- rabbit anti-mouse
FITC- rabbit anti-human fibrin(ogen)
normal mouse IgG
ABC complex/HRP
Dako A/S
HRP-anti-rabbit IgG (NA934) Amersham Pharmacia
gold-anti-mouse (GAR-10)
silver-enhancement kit 
Sigma Chemical Co.
9211S (anti-phospho p38MAPK) New England Biolabs
Oregon green 488-annexin V Nexins Research
Human vWf * Dr. Thierry Burnouf (Centre Regional de Transfusion
Sanguine, Lille Cedex, France
Prothrombin, thrombin
Factor Va, Xa
Department of Biochemistry, University of Maastricht
24; 307
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Convulxin (IV) and CRP (III and IV)
CVX was purified from the venom of Crotalus durissus terrificus by gel-filtration and
anion-exchange chromatography. After gel-filtration, the most platelet-aggregatory
fractions were applied to a QAE polystyrene-column and eluted with a salt-gradient in
50 mM Tris (pH 7.5). The active fractions were dialysed, and then concentrated with
the same column107.
Cross-linked CRP, NH
2
-Gly-Cys-Hyp-(Gly-Pro-Hyp)
10
-Gly-Cys-Hyp-Gly-OH, was
synthesised with Fmoc-chemistry2 and cross-linked with 3-(2-pyridyldithio)-propionic
acid N-hydroxy-succinimide ester and dialysed against 10 mM acetic acid.
Blood collection and platelets (I-IV)
Free flowing blood was collected from healthy volunteers, who denied having taken
any medication during the previous 10 days. The anticoagulants were PPACK, 90 mM
sodium citrate adjusted for the donor’s haematocrit271 and 131 mM acidic citrated
dextrose (pH 4.5) for preparing plasma-free platelets either by gel-filtration311 or wash-
ing133. Platelets were suspended in Hepes-buffer (3.5 mM Hepes, 137 mM NaCl, 3
mM NaH
2
PO
4
, 5.6 mM glucose, 2.7 mM KCl, 0.35% bovine serum albumin (BSA),
pH 7.4). Concentrations of CaCl
2
 and MgCl
2
 depended on the experimental set-up.
Final concentrations of divalent cations were also measured from differently antico-
agulated blood and PRP.
Preparation of adhesive surfaces
Plastic Thermanox/Permanox (I-IV), glass coverslips (FIMS) (III-IV) or multiwell
plates (prothrombinase experiments and phosphorylation analysis) were coated with
collagens (I-III), CRP (III-IV), CVX and fibrinogen (IV) or BSA (II-IV) by incubat-
ing for 1 hr at room temperature. In Paper I, collagens were sprayed on coverslips 10
times, alternating with a neutralising buffer and incubated 1.5 hr at 35°C to optimise
fibril formation142; 340.
Fibrin from fibrinogen (2 mg/ml) was formed in the presence of 2 mM CaCl
2
 and
human α-thrombin (0.9 U/ml). Fibrin from citrated plasma was generated by recalcifi-
cation (4 mM CaCl
2
) and treatment with same amount of thrombin or equivalent amount
of reptilase.
Whole blood perfusion (I and II)
To study platelet-collagen interaction and adhesion-based activation events whole blood
perfusion technique was chosen, because it allows sequential analysis of the events
under in vivo-like conditions inducing the effect of other cells and shear-rate271.
Perfusions were carried out in Badimon’s parallel-plate perfusion chambers with de-
fined rheological characteristics8. PRP was labelled with tritium–labelled 5-hydroxy
tryptamine (3H-5-HT), and whole blood was reconstituted without adjusting the plate-
let counts (I). Blood aliquots were recirculated through the perfusion chambers for 5
min (I), or were allowed only one passage (I-II). The deposited 3H-activity was meas-
ured by liquid scintillation counting. Whole blood samples were solubilized with a qua-
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ternary base-isopropanol mixture (1:1), bleached with H
2
O
2
 and acidified. Samples for
platelet count, free radiolabel and total blood radioactivity were collected before and
after the perfusion, and the values of platelet counts and of radioactivity were aver-
aged. The number of platelets deposited per coverslip area (cm2) was calculated from
the number of platelets and from their specific activity.
In Paper II, the perfused coverslips were processed for various microscopic tech-
niques. During the perfusions three samples were collected and thrombin-antithrombin
III (TAT), plasminogen activator inhibitor 1 (PAI-1), prothrombin fragments 1 and 2
(F
1+2
), whole blood clotting time and platelet count were measured to analyse the
process of coagulation in the minimally anti-coagulated blood.
For the analysis of vWf-collagen interaction under flow, glutaraldehyde-fixed erythro-
cytes in platelet-poor plasma were used to induce conditions of high-shear rate271.
Static platelet adhesion (I-IV)
Platelet adhesion assay of plasma-free platelets was performed under conditions sup-
porting adhesion of single cells and minimising platelet-platelet interaction. Adhesions
occurred under stationary conditions, at room temperature and with low platelet count
(≤ 100 x 106/ml) for specified times. Platelet adhesion was quantitated with 3H-5-HT
as described for perfusions. Similarly processed coverslips/adhesion surfaces were
also used in procoagulant assays, tyrosine phosphorylation, scanning electron microscopy
and fluorescence imaging and microphotometric system (FIMS).
Platelet aggregation (I and IV)
Aggregation of PRP or plasma-free platelets was analyzed using the method of Born34.
Aggregation was also used to generate samples for phosphotyrosine analysis in
Paper I.
Generation of platelet-derived microparticles (II)
Microparticles were generated from 300 x106 gel-filtered platelets/ml by stirring for 5-
10 minutes in the presence of 2 mM CaCl
2
. The agonists were bovine α-thrombin
(0.25 U/ml), collagen (10 µg/ml), thrombin and collagen, and calcium ionophore A23187
(10 µM). MP were separated from platelet remnants by centrifugation at 15 000 x g
for 2 minutes33 (platelet count 0 x 106/ml in Coulter cell counter).
ELISA-detection of microparticle-binding (II)
96-well microtiter plates were coated with fibrin(ogen)325, collagen192and vWf21 and
blocked with 2% BSA-PBS. 100 µl of generated MP or MP remaining in supernatant
after pre-incubation over fibrin matrices (1 hr) were incubated in duplicate wells for
one hour at 37°C. The bound MP were detected with m7E3 or SZ22 and horseradish-
peroxidase (HRP)-conjugated anti-mouse antibodies. Colour was developed with TMB
Peroxidase Substrate-system. Absorbances at 450 nm were correlated with absorbances
from 1 x 106 platelets/ml binding under similar conditions.
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Immunohistochemistry of in vivo thrombi (II)
Enderartectomy samples from nine patients were obtained within 24 hours of the onset
of the symptoms of an acute lower limb arterial occlusion. Samples were snap-frozen,
and sections were fixed with cold acetone (-20°C) for 10 min, and rinsed in PBS.
Immunohistochemical stainings were performed using the ABC complex/HRP method
at the Department of Pathology, University of Helsinki.
Immunofluorescence microscopy (II)
The perfused slides were incubated with β
3
- and P-selectin-recognising mAbs in 3%
BSA-PBS for one hour on ice and fixed in cold 1% paraformaldehyde-PBS. Then the
samples were blocked with serum, treated with fluorescent-anti-mouse antibody and
double-stained for fibrin(ogen) detection. The samples were examined using a Zeiss
epifluorescence microscope at the Department of Pathology, University of Helsinki.
Electron microscopy (EM) (I-IV) and Backscatter-analysis (II)
Perfusion samples for immuno-scanning EM (SEM) were treated as described for
immunofluorescence microscopy, but incubated with colloidal gold-coupled anti-mouse
antibody. The immuno-SEM and SEM samples were fixed with 2.5 % glutaraldehyde-
PBS for 2 hours at 22°C. For immuno-SEM, the slides were subjected to a silver-
enhancement procedure74. The samples underwent alcohol-drying, critical point-dry-
ing with CO2, and sputter-coating with gold or platinum for SEM or carbon-coating for
immuno-SEM. The samples were examined with a JEOL 820 Scanning Microscope
(SEM) or a Zeiss Digital Scanning Microscope 962 (immuno-SEM and SEM). Anti-
body-bound silver was localised by backscattered electron images, and confirmed by
X-ray microanalysis (Link Isis energy dispersive spectrometer, Oxford Instruments)92.
For transmission-EM, collagens were applied onto pioloform- and carbon-coated gold
grids and negatively stained with 1% potassium phosphotungstic acid, pH 7.3. The
samples were viewed with a JEOL 1200EX- microscope. Electron microscopy was
performed at the Electron Microscopy Unit, Institute of Biotechnology, University of
Helsinki.
Analysis for procoagulant activity (I-IV)
Procoagulant activity of platelets was analysed by four different methods. By FIMS,
the exposure of phosphatidylserine was detected from single adherent platelets with
OG488-labeled annexin V-binding (0.5 µg/ml) by measuring fluorescence at 485 nm.
Fluorescence-assisted cell sorting (FACS) was used to detect OG488-annexin V bind-
ing to platelets in suspension. In addition, formation of microparticles was detected by
side-scatter analysis of the same samples in a Coulter Epics XL-MCL FACS analyser.
Functional capacity of adherent platelets to induce thrombin formation was measured
chromogenically using S-2238 with either purified coagulation factors (III-IV) or plasma
as a source of the factors (I-II). In both methods platelets (I-IV) or MP (II) first
adhered to the investigated surfaces. After removal of unbound material, 1:20 PBS-
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diluted plasma in the presence of calcium and trace amounts of tissue factor were
added for 15 min at 37°C. Samples of the supernatants were reacted with S-2238 for
6 min and the reaction terminated with acid. Absorbances at 405 nm were related to
absorbances generated by known amounts of bovine α-thrombin (I-II).
In Papers III and IV the adherent platelets were removed from surfaces by suspen-
sion and reacted with purified factors Va, Xa and prothrombin at 37°C for 5 min with
a rate-limiting concentration of platelet/MP phospholipids (1:50 dilution). Thrombin for-
mation was stopped with EDTA-buffer and subsamples were reacted with S-2238.
Thrombin formation was measured as the linear increase in absorbance at 405 nm258.
Analysis of [Ca2+]i (III and IV)
Intracellular Ca2+-signals were analysed from fura-2 acetoxymethyl ester–labeled plate-
lets in suspension in the presence of 2 mM CaCl
2
 with a fluorometer98 and from single
adherent platelets by FIMS134. In FIMS, fura-2 fluorescence was measured in the
plane of the coverslip at excitation wavelengths of 340 and 380 nm. Fluorescence 340/
380 nm ratio values were converted pixel-by-pixel to levels of [Ca2+]
i
 by standard
calibration133.
FIMS and confocal microscopy (III-IV)
Platelets (fura-2-labeled or unlabeled) were added to coated glass coverslips mounted
in an open incubation chamber, and placed on the stage of an inverted microscope.
Changes in platelet morphology and fluorescence were simultaneously recorded with
a combined transmission phase-contrast and epifluorescence imaging system equipped
with two low-light-level intensified cameras recording fluorescence and infrared trans-
mission images. The recordings were controlled by two UNIX/Quanticell 700-compu-
ter systems (VisiTech). FIMS experiments were carried out at the Department of
Biochemistry, University of Maastricht.
Confocal images of fluorescent adherent platelets were obtained with a single-photon
confocal scanning microscope (Leica TCS-NT CLSM) equipped with an Argon laser.
Light emission was collected at 505 nm and images were captured after Kalman-
averaging for 16 lines at the Department of Biochemistry, University of Cambridge.
SDS-PAGE, Western blotting and immunodetection for phosphotyrosine
analysis (I and IV)
Platelets from aggregation were lysed with hot SDS-PAGE sample buffer containing 3
mM orthovanadate (I). Adherent platelets from several multiwell bottoms were col-
lected by transferring lysing buffer with protease inhibitors (63.5 mM Tris-HCl, pH 6.8
supplemented with 2%SDS, 10% glycerol, 1 mM orthovanadate, 1 mM phenyl-me-
thyl-sulphonyl fluoride, 50 µg/ml leupeptin and 1 mM benzamidine) from well to well
(IV). Adherent platelets from six wells yielded one sample. Suspension samples were
also lysed with the same buffer after a brief centrifugation. After boiling, samples
were centrifuged and 5% β-merchaptoethanol and 0.1 % bromphenol blue was added
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to the supernatants. Proteins were separated by SDS-PAGE (7.5 or 12%), and
electrotransferred to nitrocellulose filter. Blots were probed with desired antibodies
and developed using the ECL-technique. Video densitometry was used to quantify the
immuno-reactive proteins in western blots132.
Statistics (I, II and IV)
Student’s t-test was used for comparison of two groups and analysis of variance
(ANOVA) within multiple groups. Regression analysis was used for correlation
coefficients.
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Table 1.  Platelet deposition (PD) and morphological features of PPACK- and citrate-
anticoagulated whole blood perfusions over NC and PC (I; Fig 2 and 3)
NC PC
Conditions PD x 106/cm2 Morphology PD x 106/cm2 Morphology
500 s-1PPACK 5.4 – 2.7
Surface covered with
larger aggregates
than on PC, also
distribution more
random
3.7 – 1.7
Homogenous
surface coverage,
aggregates smaller
than on NC
500 s-1 citrate 3.9 – 0.7
Slightly smaller
aggregates, more
sparsely distributed
than above
1.2 – 0.4
Clearly less
distribution and
smaller aggregates
than above
1640 s-1 PPACK 17.8 – 10.3
Very large and high
aggregates,
erythrocytes
10.0 – 6.8
Large but lower
aggregates than on
NC, no or very few
erythrocytes
1640 s-1 citrate 7.6 – 3.1
Large but lower
aggregates than
above, erythrocytes
0.5 – 0.2
No platelets (only
at the side of the
perfusion channel)
Results
1. INTERACTION OF PLATELETS WITH COLLAGEN
1.1. Whole blood perfusion studies
Native-type collagen fibrils (NC) were isolated without the use of proteases from
bovine Achilles’ tendon containing collagen type I. NC was processed to yield monomers
(PC) by pepsin treatment. TEM of the negatively-stained collagens showed that NC
had the characteristic 64 nm banded structure whereas neutralisation and temperature
treatment as used for optimal fibril generation only produced non-banded fibrous ag-
gregates from the pepsinised counterpart (I, Fig.1). The role of different receptors in
various phases of adhesion and platelet activation was studied by comparing NC and
PC. The comparisons were started with whole blood perfusions in a parallel-plate
chamber (Badimon). GPIa/IIa was excluded by using either citrated blood (86 µM
Ca2+, 8 µM Mg2+), or the mAb 6F1. Normal cationic conditions were provided in
PPACK-blood (1.37 mM Ca2+, 0.62 mM Mg2+). High shear rate of 1640s-1 was alter-
nated with low, 500s-1, to include the effect of GPIb-vWf axis. The number of platelets
deposited per cm2 (PD, adhesion and adhesion dependent aggregate formation) was
counted by radioactively-labeling the platelets with 3H-labeled serotonin. Under all
perfusion conditions tested, NC was a more preferable substrate than PC, as summa-
rised in Table 1.
Restoration of physiological Mg2+-level (0.5-1 mM) was achieved by supplementing
the blood with 7 mM MgCl
2
 without essentially changing the Ca2+-level. Under high
shear-rate conditions (1600s-1, single passage) Mg2+-supplementation restored 66 ±
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22% of the platelet deposition measured on PC in PPACK-blood (n = 4). The essential
role of GPIa/IIa was demonstrated by the lack of platelets on PC in citrated blood
under the high shear rate. This was verified by the use of an anti-GPIa mAb (10 µg/
ml), 6F1, which in PPACK-blood nearly abolished all platelet deposition on PC by 92%
under the high shear rate conditions. The role of GPIV in platelet interaction with NC
was tested with a mAb 131.7 (5 µg/ml). In citrated blood under the high shear rate
conditions, platelet deposition to NC was inhibited 49 ± 16% by blocking GPIV (n = 5).
In citrated blood, mAb 6F1 did not further inhibit platelet deposition in the presence of
131.7 verifying that in the citrated blood the function of GPIa/IIa was already blocked
(data not shown).
Shear-dependent increase in platelet deposition on both surfaces was similar (3.3-fold
for NC, 2.7-fold for PC), suggesting that GPIb/V/IX-vWf-axis was not affected by
the different collagen preparations. This was controlled by analysing the binding of
vWf from citrated plasma to NC and PC under both stationary conditions and flow.
Under stationary conditions, NC bound more vWf than PC, but under high shear-rate
conditions using citrated PPP with washed and glutaraldehyde-fixed red blood cells, no
consistent difference in vWf binding between substrates was observed. Incubation of
the PC surface with vWf (10 µg/ml) before perfusion could not compensate for the
poor platelet deposition on PC alone at high shear rate in citrated blood (data not
shown). Finally, aurin tricarboxylic acid, an inhibitor of GPIb-mediated vWf-interac-
tion, caused ≈ 40% decrease in platelet deposition irrespective of the substrate.
The importance of collagen in thrombus formation under flow was underlined by the
observation that despite the presence of ample thrombin in the blood as a platelet
activator, only a single adherent layer of platelets was formed on coverslips in the
absence of collagen. In contrast, in the absence of thrombin, platelets formed aggre-
gates on collagen-coated coverslips, albeit they were smaller than by thrombin and
collagen co-stimulation (II, Fig. 2)
1.2. Static adhesion studies
Primary adhesion was studied under conditions which restricted platelet-platelet con-
tact and activation (I, Fig.4; III, Fig. 1). Platelets were supplemented with 2 mM Ca2+
or Mg2+. In the presence of 2 mM Mg2+, PC was always a significantly better adhesion
substrate than NC, but adhesions to both PC and NC correlated well with each other
(r = 0.83, p < 0.005), suggesting the involvement of the same receptor, i.e. GPIa/IIa.
Switching the cations decreased platelet adhesion to PC by 64 %, whereas adhesion
on NC was better in the presence of Ca2+ than in the presence of Mg2+. Platelet
adhesions on NC in the presence of Ca2+ or Mg2+ correlated with each other (r = 0.76,
p < 0.01), suggesting that the same receptors mediated adhesion under these condi-
tions, while Ca2+-dependent adhesion to NC did not correlate with Mg2+-dependent
adhesion to PC (r = 0.41), suggestive of distinct mechanisms. Blocking GPIa in the
presence of Mg2+ decreased platelet adhesion to PC by 63 % (6F1) and 52% (Gi9) (I,
Fig 5), which was to a similar extent as switching Mg2+ to Ca2+. Platelet adhesion was
not further decreased by 6F1 in the presence of Ca2+. Adhesion to NC was not inhib-
ited by these mAbs. In contrast, in the presence of Mg2+, 6F1, but not Gi9, significantly
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increased platelet deposition on NC, and reversed it to the level of adhesion in the
presence of Ca2+. MAbs against GPIb (AN51/SZ2) did not affect platelet adhesion on
either substrate (data not shown). When platelet adhesion to NC and PC was com-
pared with commercial Horm-collagen (native type I fibrils of equine tendon) or with
monomeric- or crosslinked CRP in the presence of millimolar concentrations of both
Mg2+ and Ca2+, platelet adhesion decreased in the order of crosslinked CRP >
monomeric CRP > Horm > NC > PC (III, Fig. 1A).
SEM showed that the morphology of adhering platelets was similar on NC and PC in
the presence of Mg2+only: lots of pseudopods and spreading (“fried-egg” morphology)
(I, Fig. 6). In contrast, in the presence of Ca2+, the few platelets on PC remained
spherical with few pseudopods, while on NC, platelets projected many pseudopods
and were still able to spread. Interestingly, a specific morphological feature was ob-
served in NC-adherent platelets in the presence of Ca2+: “sponge”-like platelet ghosts
that had swelled up, no longer remaining spread nor having pseudopods (Fig. 1). The
size of the sponges ranged from 2-4 µm. The membrane surface of the sponges was
rough and small vesicles were often found in their vicinity. Extensive sponge formation
was also observed in platelets adhering to immobilised CVX and CRP (IV, Fig. 4).
Activating conditions at 37°C, including rotation during adhesion, enhanced the differ-
ences between NC and PC. On PC, platelets interacting with each other kept their
morphology, but on NC, they formed small aggregates with a granular appearance
further increasing the amount of “sponges” (Fig. 2).
Figure 1. A SEM- micrograph of procoagulant platelet-sponges. Magnifica-
tion 20 000x, bar = 2 µm.
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Figure 2. SEM micrographs of morphological changes upon platelets adher-
ing to monomeric (A and B) or fibrillar (C and D) collagen at 37°C and under
rotation. Magnifications 1500x and 10 000x, bars = 10 and 1 µm, respectively.
Phase contrast microscopy showed that in comparison with pseudopod-formation and
spreading observed on NC/Horm, platelet adhesion to the monomeric or crosslinked
CRP or CVX resulted in longer pseudopods and more extensive spreading irrespective
of the cationic conditions (III, Fig. 2). On CRP and CVX, after about 3-5 min, spread-
ing was followed by rounding off, increased transparency and platelet blebbing in the
presence of Ca2+ (± Mg2+) (III, Fig. 2; IV, Fig. 4). This phase was also characterised
by the presence of small vesicular structures with rapid rotational movements. Blebs
and vesicles were also observed with Horm/NC. Spreading platelets on PC in the
presence of Mg2+, could be induced to bleb after later addition of Ca2+ (III, Fig. 2E and
F).
1.3. Aggregation
Because NC and PC differed in their capacity to activate and aggregate platelets
under flow, platelet aggregation was studied using different PRPs and GFP in the
presence of Ca2+ and Mg2+. Under all conditions tested, NC was again a significantly
more potent in aggregating platelets than PC. This became most obvious in citrated
PRP, since a four-fold higher concentration of PC was required for compatible maxi-
mal aggregation while the lag time still remained twice as long (I, Table I). In PPACK-
PRP a four-fold higher concentration of PC resulted in a similar lag time, rate and
maximal aggregation with NC. NC-induced aggregation did not differ inbetween the
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anticoagulants, except that in PPACK-PRP, the rate of aggregation was enhanced
nearly two-fold. To exclude the role of fibril formation in the extended lag time, PC
was pre-treated in neutralising buffer at 35°C for two hours before aggregation. Al-
though the fibril-forming treatment did slightly improve the aggregatory capacity of
PC, especially in citrated PRP, the lag time, rate and maximal aggregation of PC all
failed to match aggregation induced by corresponding concentrations of NC (data not
shown). With PC, mAb 6F1 prolonged the lag time and reduced the rate and maximum
of aggregation in citrated PRP (data not shown). The effect of 6F1 on PC was even
more pronounced in PPACK-PRP, apart from the lag time which was unaltered. 6F1
did not markedly affect NC-induced aggregation in citrated PRP, but in PPACK-PRP
it nearly doubled the lag time and reduced the rate two-fold, while maximal aggrega-
tion was retained (data not shown).
The aggregation data of GFP were comparable with those of PRP (I, Table II). The
aggregatory capacity of PC was severely impaired when Mg2+ was omitted, but Ca2+
was present. In the presence of Ca2+, it took longer for NC to trigger aggregation than
in the presence of Mg2+, but once aggregation was induced, the rate and maximum
were the same irrespective of the ionic environment. In the presence of Mg2+ 6F1
markedly prolonged the lag time of PC again, whereas in the presence of Ca2+, the
NC-induced lag time was shortened and the rate enhanced (data not shown). Thus,
under these conditions 6F1 enhanced NC-induced platelet activation similar to adhe-
sion.
1.4. Platelet activation
The morphological differences between the platelets interacting with either PC or NC
under static conditions suggested that the structural differences in the preparations
influenced platelet activation, although immunofluorescence analysis of the aggregates
formed during perfusion (study II) did not show differences in P-selectin expression
(data not shown). Therefore platelet activation induced by NC and PC was assessed
with tyrosine phosphorylation, Ca2+-mobilization, PS-expression and procoagulant ac-
tivity.
1.4.1. Tyrosine phosphorylation
Time-dependent changes in the tyrosine phosphorylation induced by the same concen-
trations of NC and “prefibrillised“ PC were analysed in the presence of either 2 mM
Mg2+ or Ca2+. In the presence of Mg2+, both NC and prefibrillised PC induced similar
patterns of tyrosine-phosphorylated proteins but with NC the kinetics were slightly
faster than with PC (I, Fig 7). In the presence of Ca2+, the differences accentuated, as
PC induced impaired phosphorylation. Some bands failed to appear, while the intensity
of the others was decreased. However, the kinetics of phosphorylation were also
changed with NC-induced activation: instead of a gradual appearance of tyrosine-
phosphorylated proteins in the presence of Mg2+, very intense bands suddenly ap-
peared at three minutes in the presence of Ca2+, coinciding with the onset of maximal
aggregation.
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1.4.2. Ca2+-mobilization and PS-exposure
The calcium responses of fura-2-labeled platelets were measured during the primary
adhesion process. In the medium containing Mg2+ and Ca2+, most of the platelets ad-
hering on CVX and CRP had elevated [Ca2+]
i
 after relatively short lag times of 10 ± 5
s (n = 10) and 35 ± 11 s (n = 9), respectively, whereas only a subset of the Horm or
NC-bound platelets were high in [Ca2+]
i
 after lag times of 160 ± 25 s (Horm, n = 14)
and 275 ± 40 s (NC, n = 7) (see III, Fig. 3, 4 and Plate 1). The loose contact of
platelets with PC or uncovered glass surface preserved low [Ca2+]
i
 and gave only
occasional small spikes. The PS-exposure, measured by using OG488-labeled annexin
V as a probe, followed the high and prolonged Ca2+-signal. With both Mg2+ and Ca2+
present, platelets on CVX- or CRP-coated coverslips developed strong increase in
[Ca2+]
i
, which after 1-3 min were followed by surface exposure of PS (III, Fig. 4; IV,
Fig. 3). After 20 min of the platelet-ligand contact, most of the adhered platelets were
elevated in [Ca2+]
i
 and exposed PS (IV, Table 1). Almost all of annexin V -binding
platelets exhibited a bleb-forming morphology (data not shown). Immobilised CVX
was a slightly more potent inducer of these responses than immobilised CRP, and each
were more active than NC or Horm, whereas collagen monomers, fibrinogen and
uncoated coverslips were inactive (III Fig. 4, IV Table 1 and 2). When only Mg2+ was
present and Ca2+ was added later, Horm, NC and PC supported the binding of annexin
V, albeit to about half of the extent of the CRP forms (III, Fig. 4F).
The effect of influx of extracellular Ca2+ into the platelets was studied with a Ca2+-
entry blocker antimycotic, econazole, which acts either directly with the Ca2+-channels
or by interfering with phosphorylation events. In suspension experiments with acti-
vated fura-2-labeled platelets, econazole, at a concentration of 20 µM, inhibited Ca2+-
entry by about 50% without affecting depletion of intracellular Ca2+-stores. Higher
concentrations caused platelet lysis. When applied to platelets adhering to CRP (III,
Fig. 6) or fibrillar collagens (not shown) in the presence of Ca2+, econazole changed
the shape of the calcium signals in many platelets into trains of spikes, whereas it had
little effect on the number of platelets with elevated [Ca2+]
i
. Instead, econazole consid-
erably reduced the number of annexin V-binding (III, Table 1) and bleb-forming plate-
lets (not shown). Similar [Ca2+]
i
 spiking, but of lower amplitude, was observed with
external EGTA, suggesting that econazole at this concentration inhibited the influx
considerably (III, Fig. 6). Platelets that were spread on PC in the presence of Mg2+
were low in [Ca2+]
i
, but upon Ca2+-addition, showed a potent influx signal consisting of
a prolonged rise in [Ca2+]
i
 or a train of [Ca2+]
i
 spikes (III, Fig. 7), which were followed
by bleb formation in many cells (III, Fig. 2E and F). This bleb formation could be
inhibited by econazole (not shown). The effect of Ca2+-addition was not observed in
platelets binding to fibrinogen.
Confocal fluorescence microscopy demonstrated that the blebbing platelets seen in
phase contrast microscopy were indeed the PS-exposing platelets on CRP, CVX and
fibrillar collagens. On all these adhesive surfaces, groups of small annexin V-binding
vesicles were observed, putatively remnants of detached platelets or MP. Confocal
images of OG488-annexin V-fluorescence showed that many CRP- or Horm-bound
platelets in the presence of Mg2+ and Ca2+ had a balloon-like appearance with associ-
ated bleb-like structures (III, Plate 2). Similarly, NC- and CVX-, but not PC-bound
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platelets showed vesicles close to the surface, often with balloon-shaped forms at a
few micrometers above the surface (data not shown).
1.4.3. Procoagulant activity
The capacity of NC, PC and collagen-related molecules to catalyse thrombin forma-
tion by exposing negative phospholipid surface was assessed from platelets that had
first adhered in the presence of Mg2+ or Ca2+. Subsequently, if required, the presence
of an equal amount of external Ca2+ necessary for procoagulant activity was provided
by a short incubation step. Procoagulant capacity was measured by using various
methods, which produced essentially similar results. With a method using diluted plasma
as a source of coagulation factors, platelets that originally adhered to NC in the pres-
ence of Ca2+ were capable of generating the most thrombin, while in the presence of
Mg2+, no significant differences appeared between NC and PC (I, Fig. 8). When
related to the number of adherent platelets, thrombin formation as calculated from a
standard curve using bovine α -thrombin, was 11 ± 4 (PC, Mg2+) < 18 ± 11 (NC, Mg2+)
< 30 ± 15 (NC, Ca2+) µUx106 platelets-1 x min-1. Similar results were obtained when
assessed from platelets removed after the adhesion step using purified coagulation
factors. In the presence of Mg2+ and Ca2+, the prothrombinase activity was stimulated
3-5-fold upon platelets that had been incubated with CRP, CVX or fibrillar collagens,
while platelets on PC did not stimulate the thrombin formation (III, Fig. 5), unless the
adhesion step was followed by addition of exogenous Ca2+.
In addition to static experiments, perfusion of minimally anticoagulated blood over na-
tive-type collagen fibrils was shown to increase thrombin formation in the blood as
evidenced in two-fold faster whole blood clotting time in the blood in contact with
collagen compared with collagen-free control surfaces (II, Fig. 1).
1.4.4. Role of glycoprotein VI and Ia/IIa in collagen-induced procoagulant
response
6F1 and Fab fragments in a limited amount of anti-GPVI containing serum obtained
from a patient with autoimmune thrombocytopenia were used to investigate the roles
of GPVI and GPIa/IIa in the procoagulant response. On Horm, 6F1 reduced the number
of annexin V-binding platelets down to 16 ± 4% of control values (n = 4) and anti-
GPVI Fab to 9 ± 3% without affecting adhesion (n = 6). On CRP, 6F1 only decreased
the number of annexin-V-positive platelets by 5 ± 6% (n = 5). In contrast, anti-GPVI
Fab fragment reduced the amount of positive platelets down to 15 ± 2% on CRP (III,
Fig. 8), and to 26.3 ± 3.5% (n = 10) on CVX.
2. FORMATION OF PLATELET-DERIVED MICROPARTICLES
2.1. Whole blood perfusions
Experiments in which native-like collagen fibrils (Horm) were perfused with minimally
anticoagulated blood resulting in thrombin formation before and during the perfusion
(II, Fig.1) showed in addition to ample fibrin with trapped erythrocytes, distinct aggre-
gate morphology from the aggregates formed under full anticoagulation (II, Fig 2A
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and 3A). In SEM, these aggregates had a granular appearance and had small (< 1 µm)
vesicles associated with them, likely to represent platelet-derived MP generated dur-
ing thrombus formation (II, Fig.3). Similar particles were also adherent to multistranded
fibrils of fibrin projecting from platelet aggregates. Presumably, the vesicles originated
from these aggregates. In contrast, the surfaces of platelet aggregates generated un-
der full anticoagulation were devoid of vesicles, but revealed multiple developing
pseudopods.
The thrombi were stained for GPIIb/IIIa and P-selectin, markers reported to reside
also on MP. Immunofluorescence detection of the thrombi with these markers and
double-staining for fibrin(ogen) showed that 1) the small, granular material was plate-
let-derived, and 2) the size of this material was smaller than could be expected for an
adhering platelet, and 3) the platelet-derived material resided along fibrin (II, Fig. 4).
To confirm the origin and to aid in differentiation of MP from platelet remnants, immuno-
SEM with X-ray microanalysis was required. This was achieved by silver enhance-
ment procedure, which increased the backscattered electron signal of gold-conjugated
antibody bound to either anti-GPIIb/IIIa or P-selectin antibodies. The silver-enhanced
emission signal localised platelets and small granular dots (< 1µm) along fibrin (II, Fig.
5). The size of these particles varied, starting from approximately 100 nm. X-ray
microanalysis of the backscattered electron -micrographs, verified the presence of
mAbs by silver peaks. 19 of 25 backscattered electron-positive particles regarded as
MP were found positive for silver, while ten corresponding spots in the samples treated
with control mAb X63 were all devoid of silver. Immuno-SEM of the perfused coverslips
was feasible only in selected areas devoid of multilayered structure, whereby quantita-
tive evaluation of MP was not possible with this technique .
In addition to in vitro thrombosis experiments, the presence of MP was detected in
thrombi or thromboemboli generated in vivo. Samples were obtained during embolec-
tomy from patients suffering an acute lower limb arterial occlusion. These thrombi
showed the typical morphology with layers of tangled fibrin strands and platelet aggre-
gates (II, Fig. 6). In areas among platelet aggregates, a stranded pattern of fine granu-
lar GPIIb/IIIa- and P-selectin-specific staining was detected, suggestive of an align-
ment with fibrin. The size of this material also appeared smaller than platelets.
2.2. Analysis of the properties of microparticles
The indication of MP adherence to fibrin during thrombus formation, led us to test the
ability of MP to bind to fibrin(ogen) in vitro. In an ELISA developed for the purpose,
binding of MP to fibrin(ogen) was also compared with that of collagen and vWf. MP
were generated by various agonists and carefully separated from platelet remnants.
The co-stimulation of platelets by thrombin and collagen produced more fibrinogen-
binding MP than either of these stimuli alone, and the most MP were induced with
calcium ionophore A23187 (data not shown). Measured by the binding of anti-GPIIb/
IIIa mAbs, MP were found to prefer binding to fibrinogen over fibrin, collagen and
vWf  (II, Table 1). MP binding to fibrin(ogen) was only partially blocked by the peptides,
RGDS and KQAGDV used either at 90 or 290 µM concentration.
The functionality of matrix-bound MP was assessed by their capacity to act as a
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procoagulant surface (II, Table 2). The procoagulant potential of fibrin-bound MP was
81 ± 23% (range 37-103%, n = 8) of that generated by platelets bound to fibrin from
suspensions of 300x106 cells/ml. In comparison with thrombin-generated fibrin, reptilase-
generated fibrin seemed to bind less MP, whereas no significant difference was ob-
served in platelet binding.
3. REGULATION OF MICROPARTICLE FORMATION
3.1. Effect of adhesion on PS-exposure and microvesiculation
When given to plasma-free platelets in suspension in the presence of both Mg2+ and
Ca2+, the GPVI-activating agonists CRP (2.5 µg/ml) and CVX (50 ng/ml) induced
rapid and complete aggregate formation and prolonged Ca2+-responses, whereas flow
cytometric analysis of PS exposure by OG488-labelled annexin V showed only mini-
mal binding (IV, Fig. 1), and no MP-formation (data not shown). Four times higher
dose of CRP and CVX generated [Ca2+]
i
 of micromolar levels, increasing the fraction
of PS-exposing platelets only to 10-14% after 10-20 min of stimulation (IV, Fig. 2). The
contradictory responsiveness of platelets bound to immobilised GPVI-ligands (see 1.4.2.)
prompted us to test whether platelets could be sensitised to procoagulant response by
adhesion. Fibrinogen was chosen as an effective adhesive surface, without inherent
procoagulant activity.
A low dose of CVX or CRP, i.e., a dose ineffective in induction of PS exposure and
microvesiculation in suspended platelets, induced increases in [Ca2+]
i  
in almost all fi-
brinogen-adherent platelets (IV, Table 2). In part of the platelets, the prolonged rise in
Ca2+, caused an exposure of annexin V -binding sites and bleb formation after 5-10
min (IV, Fig. 5). CRP acted similarly, but 2 nM α-thrombin did not cause PS exposure,
although it did induce a prominent increase in [Ca2+]
i 
(IV, Table 2). The prothrombinase
assay confirmed the procoagulant effect of GPVI-stimulation in fibrinogen-adherent
platelets resulting in a 2-3-fold increase in the rate of thrombin formation (data not
shown). SEM-analysis showed that in time, many of the spread platelets formed frag-
ments (microvesicles), especially at the fringes of the platelets (IV, Fig 6). After 5-15
min, some of the platelets were flat with extensive fragmentation, while others rounded
off into “sponges”. Again, stimulation with 2 nM α-thrombin only increased spreading
of the platelets (data not shown). Similarly, phase contrast microscopy of GPVI-acti-
vated fibrinogen-adherent platelets showed the presence of blebbing and ballooning
species (data not shown).
3.2. Effect of p38 MAPK, calpain and caspases in the GPVI-induced activa-
tion of fibrinogen-adherent platelets
Recent reports have associated blebbing and microvesiculation with apoptosis and
calpain activity. We therefore analysed the effect of p38 MAPK and calpain inhibition
on GPVI-mediated microvesiculation. First, we measured the activation of p38MAPK
and compared it in suspended versus fibrinogen-adherent platelets. In both cases, ad-
dition of CVX and CRP increased the degree of phosphorylation of p38 MAPK , but in
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adherent platelets both the basal and stimulated levels of activated p38 MAPK in
relation to total p38 MAPK were higher than in suspended platelets (IV, Fig. 7 and
Table 4).
The involvement of p38 MAPK in the GPVI-induced procoagulant response was studied
with an inhibitor of the p38 ATP-binding site, SB203580. SB203580 (2 µM) partially
inhibited the CVX-induced blebbing response, but it did not affect PS exposure (IV,
Fig. 8, Table 3). This experiment was carried out with aspirin-treated platelets in the
presence of apyrase to exclude thromboxane A
2 
-mediated activation processes.
SB203580 reduced CVX- and CRP-stimulated blebbing by 20-24%. The calpain in-
hibitor, calpeptin, also similarly reduced CRP- or CVX-induced bleb formation but not
PS exposure. A specific inhibitor of the activators of the ERK1/2 members of the
MAPK family, PD098059, was without an effect (data not shown). The impact of
SB203580 on fibrinogen-adherent platelets was of similar magnitude as that observed
on platelets adhering directly to CVX-coated coverslips: 39.4±7.4% and 67.3±5.3%
platelets were blebbing in the presence and absence of SB203580, respectively.
Tyrosine dephosphorylation has been claimed as a prerequisite for microvesiculation.
CRP stimulation of the platelets in suspension resulted in tyrosine phosphorylation of a
large number of bands. CRP stimulation of the fibrinogen-adherent platelets gave a
similar pattern of tyrosine-phosphorylated proteins, although at a markedly reduced
intensity. In the presence of SB203580, calpeptin, or caspase inhibitor I, these bands
re-appeared suggesting involvement of these signalling and effector pathways in the
generation of MP (Fig. 3, see below).
Figure 3. Effects of p38 MAPK (SB), calpain (cal) and caspase (cas) inhibitors
on tyrosine  phosphorylation patterns in suspended and in fibrinogen-adher-
ent platelets after 10 min activation with 5 µg/ml of CRP. Immunodetection of
the samples with A) tyrosine phosphorylation (4G10) and  B) total GPIIb (SZ22).
d = control  with the DMSO-vehicle. Note the effect of albumin around the 60
kDa proteins in the samples from adherent platelets.
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Discussion
1. SIGNIFICANCE OF NATIVE-TYPE FIBRILS IN COMPARISON WITH
PEPSINISED MONOMERS
The preservation of the native-like conformation of collagen depends strongly on the
source of material and the method of isolation205. As a structural component of tissue,
generally existing as complexes with other poorly soluble molecules, isolation of colla-
gen has often involved the use of proteases. Thus, unfortunately, collagen monomers
obtained by proteolytic isolation have often been used also as native-type fibrils in
platelet-interaction studies. However, collagen fibril-formation has been shown to de-
pend on the initiating process which is seriously impaired by the removal of
telopeptides136; 142; 160; 188; 193. This was clearly shown in TEM by the formation of non-
banded aggregates, when extensively pepsinised collagen type I monomers (90% pure)
were treated to induce fibrils (for effects, see I, Fig 1). Although several early studies
had shown the importance of the tertiary and quaternary structure of collagen in plate-
let aggregation38; 67; 100; 156; 182; 220; 232, the discrepancies of results obtained using  either
monomer-derived or true fibrils have previously escaped close scrutiny.
Indeed, paying attention to structural properties of collagen has proved to be essential,
particularly in platelet function studies. The findings of the current series of studies
showed that in whole blood perfusions, platelet deposition on pepsinated collagen in
comparison to true fibrils was impaired under all conditions. Furthermore, under sta-
tionary conditions, collagen monomers were unable to induce intracellular Ca2+-mobi-
lisation, PS-exposure or procoagulant response in platelets without exogenous Ca2+-
influx, although under flow conditions, they could still induce aggregate formation and
granule secretion. Thus, native fibres provide essential information on total functional
effects of collagen on platelets. While this study was in progress, this has been realised
in several outstanding papers clarifying the role of structural determinants of collagen
on platelet adhesion and activation221; 222; 282; 326.
The current view holds the quaternary collagen structure important for platelet activa-
tion because the receptor regarded responsible for signalling, GPVI, is thought to re-
quire dimerization for its function58; 331. The same motif of efficient cross-linking through
the multimeric collagen fibrils is also characteristic of the GPVI-specific ligands CRP
and CVX107; 176. However, in addition to providing optimal presence or spacing of G-P-
P*-triplets, the native collagen-structure may contribute other interactive determinants.
The pepsin-sensitive non-helical telopeptides were found to contain cation-independ-
ent platelet-binding sites in both monomeric and polymeric collagen349. These telopeptide
domains are considered to be the most immunogenic part of the collagen molecule35.
Recently, polyclonal anti-collagen antibodies effectively inhibited the formation of thrombi
on injured endothelium299. Telopeptide domains have also been suggested to act as
binding sites for proteoglycans and thrombospondin, which in turn may influence plate-
let-collagen interactions indirectly60; 286. Finally, especially in the case of isolating un-
disturbed fibres, the additional fibril components such as decorin or the FACIT-colla-
gens may still remain present in the final collagen preparate, and could thus be capable
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of engaging additional receptors  and modulating platelet responses. As a summary,
not enough attention has previously been paid to the structural determinants of colla-
gen which influence all stages of platelet adhesion and adhesion-dependent activation.
Several structural features of the native collagen may be vital for full platelet function,
and their role in haemostasis needs to be elucidated further.
2. INTERACTION OF PLATELETS WITH COLLAGEN
The importance of GPIa/IIa in platelet deposition on collagen types I-VIII under flow
conditions has long been known, but nonetheless, studies on the structural require-
ments of this interaction have remained scarce268. The whole blood perfusion results
presented in this thesis showed that under the high-shear rate conditions, GPIa/IIa was
absolutely essential for platelet interaction with monomeric type I collagen in contrast
to native-type fibrils. These results were recently confirmed by Savage et al who
showed that surface coverage and thrombus volume were dramatically decreased by
anti-α
2
 mAb (R2-7E4) on pepsin-solubilised but not on acid-insoluble collagen283. In-
terestingly, our fully-pepsinised monomers remained inert despite the collagen prepa-
ration having been neutralised and temperature-treated to “induce fibrils”, while in
Savage’s study, platelet deposition comparable with acid-insoluble collagen was re-
gained by fibril-forming procedures even in the presence of GPIa/IIa blockade. Similar
results of almost fully-inhibited surface coverage on collagen monomers were also
obtained by using anti-α
2
 mAbs 6F1 and 176D7, but in contrast to studies by us and
Savage et al, the inhibitory effect of these mAbs was the same irrespective of the
fibrillar or monomeric status of the collagen used326. The discrepancy between these
results might once again depend on the different sources of the collagens or the extent
of proteolysis, since in both studies, native-like “banded” collagen could be formed by
the fibril-inducing treatment in contrast to the staggered aggregates derived from our
fully pepsinised monomers. Pepsin-proteolysis for 48 hours has been shown to result
only in a partial cleavage of the non-helical telopeptides of type I collagen188, and for
example in the study of Savage et al., collagen was pepsinised only for 18 hours.
The fact that complete loss of platelets on monomeric collagen was shown to occur
especially under high shear-rate and independently of the GPIb-vWf-axis, demon-
strates the importance of GPIa/IIa as a shear-resistant receptor in microvasculature
and occluded arteries. This was also evident in the study of Savage et al, in which
increased lag time and reduced thrombus volume on reconstituted collagen fibrils was
observed only under the shear rate of 1500 s-1 283. Moreover, in our study, the shear-
dependency of GPIa/IIa was reflected by 60% loss of platelet deposition on collagen
fibrils when comparing citrated blood with PPACK-treated blood at high shear-rate. In
comparison with the anticoagulant switch-based reduction in platelet deposition at the
low shear rate of 500 s-1, the observed loss was twice as high. The result of shear-
dependent loss in platelet deposition is further highlighted by the fact that under station-
ary conditions, platelet adhesion to fibrils was completely independent of GPIa/IIa,
also previously shown by others215; 217; 326. Savage et al found a 50% inhibitory effect
of GPIa/IIa blockade on fibrillar collagen only under low surface-coating concentra-
tions282. The low concentration was in the same range as used in our study. A note
must be made on the different ways of inhibiting GPIa/IIa: chelation of cations by
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citrate reduces not only the amount of Mg2+, but also Ca2+, which is essential for the
function of GPIIb/IIIa288; 289. The use of an anti-GPIa mAb is probably more specific
and its effect may be preserved even upon changes in the receptor affinity. Hence, in
comparison to total abolishment of platelets observed with anti-GPIa mAb283, our ob-
servation of the low platelet deposition on monomeric collagen observed under the low
shear-rate conditions in citrated blood probably reflects loss of inhibition of GPIa/IIa,
or compensation by other receptors. Interestingly, a recent study using α2-I-domain as
an inhibitor of platelet–collagen interaction could show inhibitory activity only under
the low shear-rate flow conditions, whereas at high shear-rate, only the interaction to
extracellular matrix was blocked by the presence of the I-domain 94. Finally, the impor-
tance of GPIa/IIa under high shear-rate conditions is also advocated by the recent
studies which demonstrate high GPIa/IIa expression as a risk factor for thrombotic
complications46; 218; 279. We propose that employing pepsinised monomers in flow stud-
ies could provide a useful tool when analysing the role of genetic variability of GPIa/IIa
in platelet-collagen function181; 194.
 In marked contrast to collagen monomers, the native type I collagen fibrils could still
retain over 40% of platelet deposition under flow in the absence of functional GPIa/
IIa. About half of the remaining platelets were lost when GPIV was simultaneously
blocked with a mAb, in agreement with previous studies proposing a role for GPIV in
the early phases of primary adhesion85; 199. A detailed analysis of platelet adhesion to
fibrillar collagen under stationary conditions showed a role for GPIV both in primary
adhesion and in activation of GPIIb/IIIa in the absence of functional GPIa/IIa. Several
other previous studies have dismissed the role of GPIV in platelet-collagen interac-
tion73; 171; 202; 266; 344. However, in only one of them, GPIa/IIa was simultaneously inhib-
ited with GPIV, but in turn, pure collagen monomers were used as the substrate in
contrast to fibrils, thus masking the effect of GPIV202. Interestingly, the absence of
both functional GPIa/IIa and GPIV could not completely abolish platelet deposition on
collagen fibrils in comparison to the total loss of adhesion observed on monomers.
Hence the native fibril structure contains the capacity to stimulate thrombus formation
by several mechanisms. In this aspect, a study of the role of the 65 kDa receptor
recently sequenced would be of immense interest55. Altogether, these results suggest
that several receptors are needed to safeguard the primary adhesion during haemosta-
sis, as supported by clinical observations stating that more than a single partial platelet-
collagen defect is needed for a bleeding disorder18; 81.
GPVI has been shown to be the major receptor responsible for advanced platelet
activation, recognition of which also requires native-type collagen structure. In our
study, this was directly demonstrated by the ability of anti-GPVI Fabs to inhibit the
culminating activation event in platelets, the procoagulant response, induced by fibrillar
collagen. This was further confirmed by the GPVI-specific ligands, CRP and CVX176;
244. The platelet-activating capacity of GPVI enhanced all the analysed signalling re-
sponses ([Ca2+]
i
, PS-exposure and procoagulant function and changes in morphology,
i.e. “sponges”, see later) in platelets adhering to either CVX or CRP, in comparison
with native collagen fibrils. Fibrillar collagen-activated platelets in solution possessed
slightly faster and more potent tyrosine phosphorylation responses than monomer-ac-
tivated platelets. Furthermore, as supported by the amounts of platelets deposited dur-
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ing perfusion, morphological analysis of the thrombi formed on collagen fibrils in con-
trast to monomers revealed further activation in the form of larger and higher aggre-
gates and the likely formation of fibrin (i.e. presence of erythrocytes). This accords
with the previous results showing impaired aggregate formation of GPVI-deficient
platelets under flow211. However, perfusion studies using CRP demonstrated that GPVI
is not sufficient to bind platelets, even under conditions of a low shear-rate326. Until the
recent cloning of GPVI, detailed research of the roles of GPVI in platelet-collagen
interaction has been hampered by the lack of available antibodies58.
Substrate binding of integrins is regulated by affinity modulation of the receptors149; 289.
GPIa/IIa has been reported to have different binding affinities depending on the substrate,
the divalent cations present and the platelet-activating agonist123; 161; 242; 278; 297. Indeed,
we found that anti-GPIa mAb 6F1, but not another antibody of the same isotype, Gi9,
increased stationary platelet adhesion to native type collagen fibers, whereas they both
were inhibitory in adhesion to monomers, as has also been previously established62; 221.
Others have also published similar results, although no relevance has been attached to
this phenomenon213. Recently, affinity modulation of GPIa/IIa required for soluble col-
lagen binding was described to be induced by ADP, thrombin and CRP158.
In addition to possible GPVI-mediated signals regulating GPIa/IIa activity through af-
finity modulation, the engagement of GPIa/IIa with its ligand might induce intraplatelet
signalling in itself. This was implicated by the capacity of native heparin proteoglycans
to inhibit aggregate formation, but not the primary adhesion of platelets190, and the
collagen- but not CRP-induced procoagulant response (unpublished results). The acti-
vation of GPIIb/IIIa, the prerequisite of aggregation, was proposed to be mediated by
GPIa/IIa in several current studies, taking into consideration the role of GPVI172; 222.
Although GPVI seems to be essential for platelet activation and also for procoagulant
activity (see later), GPVI-deficient patients do not suffer from severe bleeding331.
Furthermore, although, its exact role in the sequence of events is currently unclear
apart from adhesion, several studies have suggested a role for GPIa/IIa in platelet
signalling5; 150; 152; 164; 168. We observed that fibrillar and monomeric collagen–induced
protein tyrosine phosphorylations in platelets in suspension were similar in the pres-
ence of Mg2+, and additionally, both were decreased in the presence of Ca2+. This
inhibitory effect of Ca2+ suggests the involvement of GPIa/IIa in collagen-induced
signalling, since it contests the major role of the cation-independent GPVI.
Recently, the role of vWf in platelet-collagen interaction has also been re-examined,
and a thrombus-growing role under low shear-rate conditions, together with a throm-
bus-stabilising role under high shear-rate conditions were introduced, in addition to the
previously-characterised essential shear-dependen tethering-function of vWf264; 282.
Combined, these results suggest revision of the two-site two-step model (see figure
next page).
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Figure 1. Schematic model for platelet-collagen interaction revising the pre-
vious two-site two-step model based on new data.
Whereas previously research has been concentrated on finding “the one and only”
receptor for adhesion or activation, it now seems more likely that platelet-collagen
interaction is an event directed and regulated by multiple receptors. The development
of solid-phase peptide-synthesis has allowed more precise localisation of relevant se-
quences in collagen. Production of overlapping peptides covering an area of interest or
containing an activating determinant allow the study of their principal mode of ac-
tion176; 177; 216; 326, and the availability of receptor-specific antibodies will further assist
in clarifying the sequence of events occurring during platelet-collagen interaction. Fu-
ture experiments will discover new receptors and establish which of the receptors
participate in platelet-collagen interaction, and how the interplay between different
receptors affects adhesion and the adhesion-dependent activation.
3. PLATELET-COLLAGEN INTERACTION AND THE GENERATION OF
PROCOAGULANT ACTIVITY
The powerful role of the collagen-platelet interaction was shown in this study by the
absolute collagen-dependence of thrombus formation under flow conditions despite
the excessive amount of thrombin present (see II, Fig. 2). Furthermore, under station-
ary conditions in vitro, adhesion to native-type collagen and collagen-related substances,
CRP and CVX, was shown to transform platelets from inactive to actively procoagulant
cells generating thrombin. These results are in line with those of Kirchhofer et al who
under flow conditions showed the importance of the first collagen-adherent platelet
layer in the generation of fibrin174.
The procoagulant capacity of collagen- or collagen-related substrate-adherent plate-
lets was reflected both in their membrane asymmetry by exposure of negatively charged
aminophospholipids, e.g., PS, and also by changes in platelet morphology. Procoagulant
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platelets lost their flat or stellate adherent form and became rounded and enlarged
compared with their resting size. In phase-contrast microscopy, this stage could be
described as transparent and blebbing, whereas in high-resolution SEM platelets ac-
quired a spongy appearance with small vesicles, either attached to them or in their
vicinity. Such spongy morphology has been previously described in connection with
prolonged incubation of platelets in high exogenous Ca2+-concentrations314. This mor-
phology was dependent on the presence of extracellular Ca2+, and was absent in plate-
lets adhering to collagen monomers or fibrinogen, the latter even after stimulating the
adherent platelets with exogenous thrombin. It is probable that the observation of sponges,
although informative, is an artefact due to both the method of fixation and the state of
individual platelets in an experiment, which reflects the loss of membrane surface
integrity both as PS exposure and microvesiculation. As such, it may be useful for
analysis of the procoagulant status of platelets. The procoagulant transformation of
platelets into sponges or blebbing cells should be recognised as the final step in the
shape change of platelets following spreading, unless aggregate formation ensues.
There is evidence for appearance of this morphology in platelets in direct contact with
collagen in haemostatic plugs, whereas platelets, which had deposited further away,
retained their form336. In accordance, most of the larger thrombi were shown not to
stain for fibrin, but instead fibrin strands originated from single platelets or small
microaggregates174. Finally, recent studies of platelet-interaction with fibrin-clots have
also demonstrated increased procoagulant activity and generation of MP from the
interacting platelets151; 184. Although the effect has been identified to be mediated by
vWf via GPIIb/IIIa or GPIb29, the striking similarity between the molecular assembly
of both collagen fibrils and fibrin fibres could additionally involve receptor multimerisation-
based activation.
To our knowledge, this is the first study to show the generation of platelet-derived MP
under experimental conditions of blood flow. Previously, increased MP formation has
been associated with various coagulation aetiologies in vivo143, and recently, also ex-
treme high-shear rate conditions alone were shown to induce formation of MP207. We
found MP to be generated using both immobilised collagen and soluble thrombin as
platelet-agonists, thus mimicking severe haemostatic injury, but also in thrombi derived
from in vivo. The MP so formed had the capacity to associate with locally produced
fibrin, a finding later confirmed by others141. Fibrin associated-MP could effectively
catalyse tissue-factor initiated thrombin formation. Similar results were shown in a
study of rabbits where radioactively-labelled platelet-derived vesicles both accumu-
lated in bleeding time lesions and shortened the bleeding time201. We propose that the
shedding and binding of MP could have also other roles, e.g., as modulators of inflam-
mation239 or fibrinolysis79, in addition to procoagulant action. Recent studies have now
introduced several MP-provided molecules as effectors of leukocyte and endothelial
cell function (see Table 2 in Review of literature). Increasing data show that the cells
of the vasculature are in reciprocal action with each other. Platelets themselves are
known to influence these interactions, but they may do so also through the shed
microparticles, the recently identified exosomes135, or via soluble agonists, such as
sphingosine 1-phosphate138.
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4. COLLAGEN-INDUCED SIGNALS THAT GENERATE MICROPARTICLES
The real-time fluorescent analysis of procoagulant response in platelets adhering to
collagen- and collagen-related substrates allowed us to study the signalling reactions of
[Ca2+]
i
, PS-exposure and morphological changes simultaneously, and to relate them
together. The various substrates exhibited differential capacity to induce procoagulant
response: CVX, a multimeric snake venom protein> CRP, the collagen-related
crosslinked peptide > CRP monomers > native-type collagen fibrils. In contrast, colla-
gen monomers and fibrinogen were inactive. Fibrillar collagen and GPVI-receptor
ligands performed this function almost cation-independently, whereas collagen monomer-
or fibrinogen-adherent platelets could be induced to express PS and form sponges or
blebs only after adding exogenous Ca2+, or Ca2+ and GPVI-stimulating ligands, respec-
tively. This suggests that integrin-mediated adhesion combined with a signal causing
potent Ca2+-influx would be sufficient to generate a procoagulant response.
The small quantities of GPVI Fabs available allowed only restricted studies on the
inhibitory effect of GPVI-blockade. On platelets adhering to fibrillar collagen, CRP
and CVX, the platelet preincubation with GPVI Fabs resulted in almost complete abo-
lition of PS-exposure, in contrast to the weaker effect of anti-α
2
 mAb 6F1, on collagen
and CRP. Combined, these results support the role of GPVI as a key receptor respon-
sible for the ultimate platelet activation. Several studies have emphasised the role of
GPVI in platelet aggregate function and as the inducer of effective signalling involving
tyrosine phosphorylation and activation of PLCγ2330. However, these studies could not
completely disclose the role of GPIa/IIa, since for example CVX was found to be the
most potent of the activating adhesion surfaces, and CVX has been postulated to be
also a ligand of GPIa/IIa157. More studies involving specific receptor antibodies and
peptides are clearly needed to achieve a conclusion of the matter.
Interestingly, platelets which were activated with GPVI-ligands in suspension exhib-
ited potent aggregatory and [Ca2+]
i
-increasing responses, but poor procoagulant trans-
formation. Conversely, immobilisation of platelets to these ligands or CRP/CVX-acti-
vation of fibrinogen-bound spread platelets displayed high Ca2+-responses, which in
most platelets were followed by PS-exposure and platelet fragmentation analogous to
microparticle formation. This would suggest that although high and prolonged intracel-
lular Ca2+-response is necessary for MP-formation it is not sufficient71; 134; 337. Experi-
ments using the Ca2+-influx blocker econazole reflected the importance of Ca2+-influx
in the [Ca2+]
i
-elevation. However, recent reports have shown that MP-generating
agonists, such as C5b-9 of the complement system, which are considered to rely on the
Ca2+-influx as their main MP-inducing mechanism, also activate other signalling path-
ways68.
The role of calpain in microvesiculation has been controversial103. In accordance with
the previous results, we found calpain activation to participate in the generation of
microparticles but not in the loss of membrane asymmetry leading to PS-exposure104;
113; 290. Calpain has been implicated in the initial spreading of cells183, and in the hy-
drolysis of cytoskeletal proteins (reviewed in102), and it was also shown to be a media-
tor in platelet aggregation and secretion66. Calpain also seems to be needed in the final
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stages of platelet activation, i.e., microvesiculation, as evidenced by its inhibitory effect
on fibrinogen-spread platelets stimulated with soluble GPVI-ligands. This would indi-
cate that calpain activation is a reoccurring event during various steps along the plate-
let activation-axis.
Recent studies in other cells have also associated microvesiculation with apoptosis by
analogous morphological changes and the discovery of mediators of apoptotic signal-
ling pathways. For example, in endothelial cells, peroxide-evoked bleb formation dur-
ing apoptosis has been proposed to be mediated by a stress-activated protein kinase,
p38, belonging to the MAPK family148. Several other findings have also implicated
MAPK in the apoptotic process induced by several stress-related stimuli22; 31; 167; 224;
285. In the present study, evidence for the participation of two apoptosis-associated
signalling pathways, p38 MAPK and caspases, were found to be involved in
microvesiculation. Caspase-3, a protease involved in apoptosis, specifically engages
with activation events, such as PS-exposure, microvesiculation and the cleavage of
cytoskeletal protein, moesin290. All MAPK-pathway members have been shown to be
present in platelets42; 272. A specific inhibitor of p38 MAPK decreased blebbing of
GPVI-stimulated fibrinogen-adherent platelets. Furthermore, the potentiating effect of
adhesion observed in fibrinogen-adherent platelets, upon addition of soluble GPVI-
agonists, could be mediated by the increased basal activation of p38 in fibrinogen-
adherent platelets. CRP and CVX also further increased p38- activation both in sus-
pended and in adhering platelets, but the observed increase, relative to the total amount
of p38MAPK, was higher in adherent platelets. The function of p38 is postulated to be
mediated through cytoskeletal re-organisation by proteins such as MAPK-activated
protein kinase 2224, which, in turn, phosphorylates the 27 kDa heat-shock protein, modu-
lating actin polymerisation148. Furthermore, it was shown that integrin-mediated adhe-
sion is mandatory for the activation of p38 MAPK by growth factors, in a way involv-
ing focal adhesion kinases235; 254.
Interestingly, phosphorylation of ERK and JNK members was found to be downregulated
by engagement of GPIIb/IIIa, in contrast to our finding of increased p38 MAPK phos-
phorylation in fibrinogen-adherent platelets42. Although the results of that study were
based on GPIIb/IIIa engagement during platelet aggregation, we observed increased
p38-activity also in GPVI-ligand-activated platelets in suspension, induced to aggre-
gate fully. This implies differential regulation of MAPK family members and could be
an example of cellular fine-tuning of signal transduction. This concept is further sup-
ported by the fact that we did not find any effect of the ERK-pathway inhibitor in
platelet blebbing.
Several studies have shown tyrosine phosphorylation to be an important mediatory
step in the formation of MP69; 134. A recent theory proposed that tyrosine phosphoryla-
tion is needed for the exposure of PS, whereas conversely, subsequent dephosphoryla-
tion is required for microvesiculation237. Indeed, increased tyrosine phosphorylation
was observed in platelets stimulated with GPVI-ligands in suspension. Analysis of
tyrosine phosphorylated proteins from fibrinogen-adherent platelets induced to
microvesiculate by addition of CRP, showed phosphorylation of the same proteins,
e.g., 100 kDa band, albeit at decreased intensity. The decrease was still apparent
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when decreased amounts of phosphorylated protein were standardised by using anti-
GPIIb mAb. This loss in tyrosine phosphorylated bands could be rescued by inhibitors
of p38 MAPK, calpain and caspase. However, studies with blebbing and sponge-like
platelets demonstrated fragility of procoagulant platelets, so that during preparation of
samples some material is probably lost. Hence, the role of dephosphorylation in
microvesiculation can not be confirmed by these studies, but the reversal appearance
of tyrosine phosphorylated proteins would suggest that p38 MAPK, calpain and caspase
are involved, since they either reverse the dephosphorylation reaction or inhibit
microvesiculation. Recently, the activation of p38 MAPK was shown to reside up-
stream of caspase-3 activation in an experimental cell model, and caspase-3-mediated
activation of calpain was proposed to occur in neuronal apoptosis, suggestive of a
close sequential connection of all three apoptosis-associated molecules228; 328. The similar
effects of inhibiting these modulators on microvesiculation would support this idea.
More evidence is accumulating on the importance of the signalling mechanisms regu-
lating cytoskeletal transformations in microvesiculation. This is reflected by the ability
of cytochalasin D, an actin polymerisation inhibitor, to block microvesiculation almost
completely345. Ca2+-mobilisation is required for activation of several enzymes including
calpain317, p38 activates the 27 kDa heat-shock protein, while inhibition of myosin
light-chain kinase partially prevents the generation of MP338, to mention a few. All
these routes are engaged in platelets activated through collagen. Furthermore, Wiskott-
Aldrich syndrome protein (WASP) is a non-enzymatic substrate for collagen- and CRP-
induced tyrosine phosphorylation and a substrate of calpain involved in the regulation
of cytoskeleton downstream of Rho family proteins126; 233; 303.Wiskott-Aldrich syndrome
platelets are characterised by their small size and decreased calpain content. It has
been suggested that this could relate to increased amounts of circulating calpain-rich
MP in these patients173; 238.
The severe bleeding of the Scott syndrome patients manifests the haemostatic impor-
tance of PS-exposure and microvesiculation, and the morphological transformation
upon collagen-adherent platelets could be regarded as a process of functional cell
death analogous to apoptosis. Platelet-adhesion to collagen is important for the anchor-
age of this powerful, self-catalysing activation loop of haemostasis to the correct site
at the vessel wall. Several receptors participate in this response, so safeguarding it,
perhaps, by introducing a degree of redundancy. The full platelet activation responsible
for thrombin generation is also regulated by multiple receptors of which some are
directly activating and some are co-stimulatory. The importance of each receptor in
this event will be assessed by future studies involving the use of specific antibodies and
substrate peptides. At best, the results of these studies could provide a key to develop-
ment of better treatment of thrombosis.
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Summary and conclusions
Adhesion to collagen as well as the adhesion-dependent activation of platelets are
the cornerstones of haemostasis. Despite that several platelet proteins are known to
associate with collagen, the collagen receptors responsible for the sequence of events
from the single adherent platelet to the full-blown fibrin-rich thrombus have still been
only partly characterised. The series of studies in this thesis describe new aspects of
platelet adhesion and adhesion-dependent activation. It was recognised that during
the primary adhesion, GPIa/IIa acts as a shear-dependent receptor, absolutely es-
sential for platelet binding to monomeric collagen. The native structure of fibrillar
collagen is required to permit the arrest of platelets by other receptors in concert
with GPIa/IIa, and to provide sufficient stimulus to fully activate the platelet. The
culmination of platelet activation is the procoagulant transformation. The present find-
ings show that the generation of procoagulant activity requires the receptor GPVI,
but in order to attain procoagulant status, the majority of platelets must also be ad-
herent. This emphasises the functional role of adhesion and spreading mediated by
platelet integrins GPIa/IIa and GPIIb/IIIa.
Importantly, the results of these studies highlight the relevance of nativeness of
substrates and in analytical methods. Plenty of data on platelet-collagen interaction
and activation have been obtained by using in vitro experimental set-ups, where the
characteristics of the collagen molecules used or the multifactorial nature of the re-
sponses are easily ignored. In the present work, this became evident from the shear-
dependence and essential role of GPIa/IIa, from the little-studied role of GPIV in
platelet-collagen interaction, and from the procoagulant inactivity of platelets either
bound to monomeric collagen or activated in suspension. The findings presented
here reward the use of in vivo-mimicking methods and multidisciplinary approach,
despite them having been both bothersome and time-consuming to implement.
Procoagulant transformation of platelets upon activation is featured by the expres-
sion of negatively charged aminophospholipids such as PS, by the characteristic
shape change into blebbing or sponge-like platelets and the ultimate formation of
platelet-derived microparticles (MP). The increase in Ca2+-mobilization accompa-
nied by Ca2+-influx and the activation of both the protease calpain and the p38 mem-
ber of MAPK-family were recognised as important intracellular signals for
microvesiculation. Platelet procoagulant activity consists of two distinct responses,
PS-exposure and microvesiculation, as evidenced by the inability of specific inhibi-
tors of calpain or p38MAPK to prevent the PS expression. MP generated under
conditions either mimicking haemostasis or during real thrombotic events in vivo
associate with fibrin, and fibrin-bound microparticles can further enhance formation
of thrombin. The MP so produced may also modulate other functions, e.g., by influ-
encing other cells in circulation. However, currently, the functional role of MP in
haemostasis and thrombosis remains to be further elucidated.
The heterogenic literature of signal transduction concerning the formation of platelet-
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derived MP reflects the involvement of many initial activation routes. Although the
agonists and the pathways leading to MP generation may vary, they are likely to unite
into a final common signalling pathway. These signals may be discovered with the
help of, e.g., MP-deficient patients. Moreover, MP need to be characterised more
carefully based on their origin, their functional properties and the agonist used to
stimulate their formation. Also, the methods employed to detect MP should be stand-
ardised. Resolving these issues will hopefully shed light for the physiological signifi-
cance of MP.
Altogether, the results of this thesis are concordant with the specific concept that
both the adherence of platelets and their subsequent activation are tightly controlled
processes, which preserve the haemostatic integrity by localising the maximal re-
sponse to the site of injury.
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